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List of abbreviations 
 
AGC                             Protein kinase A(PKA)/PKG/PKC-like 
ATP                              Adenosine triphosphate 
Drosophila                  Drosophila melanogaster (fruit fly)  
LATS                          Large Tumor Suppressor          
STK                            Serine/Threonine Kinase 
MST                           Mammalian sterile-20 like 
NDR                           Nuclear dbf2 related 
NTR                            N-terminal regulatory domain 
AS                               Activation segment 
MOB                           Mps one binder 
YAP                            Yes associated protein 65 (YAP65) 
TAZ                            WW domain containing transcription regulator 1 (WWTR1) 
TEAD                          Transcriptional enhancer factor TEF-1 
WT                              Wild type 
KD                               Kinase dead 
PKB                             Protein Kinase B  
PI3K                            Phosphoinositide 3 kinase 
PDK1                          Phosphoinositide-dependent kinase 1 
TSC                             Tuberous sclerosis 
ABL                             Abelson murine leukemia viral oncogene homolog 1 
JNK                             c-Jun N-terminal kinase 
EGFR                          Epidermal growth factor receptor 
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PDGF                          Platelet-derived growth factor 
PDGFR                       Platelet-derived growth factor receptor 
MAPK                        Mitogen-activated protein kinase 
S. cerevisiae                 Saccharomyces cerevisiae (budding yeast) 
S. pombe                      Schizosaccharomyces pombe (fission yeast) 
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Summary 
Protein kinases are critical players of signal transduction pathways involved in development, 
physiological and pathological processes. Deregulation of protein kinase signaling is found to be 
causal or related to varieties of human diseases, such as cancer, cardiovascular disease and 
diabetes. The human genome encodes 518 protein kinases. Approximately 60 out of them belong 
to the AGC group of Serine/Threonine protein kinases, including the ste20 like MST kinase 
family and NDR kinase family. Members of these families are highly conserved from yeast to 
men and regulate essential processes such as growth, proliferation and apoptosis. The Hippo 
pathway is a recently identified tumor suppressive network, where the MST-NDR family kinases 
form a kinase cascade regulating the downstream signaling through the effector YAP/TAZ.  
In addition to signaling through the NDR family kinases, the Hippo/MST kinases also control 
cell apoptosis bypass these classical effectors YAP/TAZ. Despite the fact that JNK, FOXO3, 
H2B are well characterized downstream targets of apoptotic MST kinases, the regulatory 
mechanisms of apoptotic MST signaling are still largely unknown.  
The human MOB family consists of six members encoded by six different genes (hMOB1A, -1B, 
-2, -3A, -3B and -3C). While as an activator for hMOB1A/B in MST-LATS/NDR kinase cascade, 
hMOB2 is a specific negative regulator of NDR kinase by competing the binding of hMOB1 to 
NDR kinase. Although hMOB3 family members share higher amino acid identity with hMOB1 
than hMOB2, hMOB3 proteins do not interact or (de)activate NDR family kinases. Hence, the 
functions of hMOB3A/B/C are completely undefined.  
A previous microarray study performed in the lab indicated that hMOB3 family members were 
deregulated in glioblastoma. In the present study, we first investigated the pathological roles of 
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human MOB3 proteins and found that hMOB3 is highly upregulated in glioblastoma. Moreover, 
mRNA expression levels of hMOB3 members correlate with survival, suggesting hMOB3 
members as potential prognostic markers. We extended the biochemical analysis by looking for 
the interaction partners of hMOB3 and demonstrated that hMOB3 binds to MST1 and inhibits 
the apoptotic cleavage of MST1 kinase. We further verified that hMOB3 promotes tumorigenesis 
of gliobalstoma cells in vivo by a U87MG derived flank model. Taken together, our results 
suggest that manipulate hMOB3 might represent a therapeutic strategy in malignant gliomas.  
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1. Introduction 
1.1 Protein kinases in organ size control 
Protein kinases are essential components of intracellular signaling pathways and mediating most 
of the signal transduction in cells. Protein kinases are kinase enzymes that modify targeted 
proteins (substrates) by catalyzing the transfer of phosphate groups to substrates’ hydroxyl group 
of serine, threonine or tyrosine amino acid side chains (1). The phosphorylation usually results in 
functional changes of substrates, such as enzyme activity, subcellular localization, binding 
affinities to other proteins and protein stability. Thus, protein kinases play critical roles by 
orchestrating signaling transductions involved in development, cell growth and differentiation. 
Therefore, deregulation of protein kinases by mutation, fusion with other kinases/proteins or 
altered expression is causal or associated with many human diseases such as cardiovascular 
diseases, cancer and metabolic diseases.  
The protein kinase complement of the human genome, also known as the kinome, encodes 518 
protein kinases and represents one of the biggest gene family of the human genome (2). To gain 
insight into kinase function and evolution, all 518 protein kinases were classified into a hierarchy 
of groups, families and subfamilies based on the sequence similarity of their catalytic domains, 
domain structure outside of the catalytic domains (2). The biggest kinase group is tyrosine 
kinases (90 kinases), followed by the CAMK (74 kinases), the AGC (63 kinases) and then the 
CMGC group of kinases (61 kinases) (Figure 1) (2). Since aberrant protein kinase signaling is 
causal or associated with the development of human diseases, protein kinases have emerged as a 
major class of drug targets for therapeutic intervention (3).  
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The development of a fully functional organ depends on the precise patterning and size-sensing 
signals. Precise control of organ size is a fundamental and critical process during animal 
development and tissue regeneration, which is a highly coordinated process involving variety of 
physiological signaling integrations. In general, the finale organ size is dependent on the cell size 
and cell number. While cell size is regulated by cell growth, the hemostasis of cell number is 
maintained by the balance between cell proliferation and cell death. The TOR and Hippo 
pathways, both of which are controlled by protein kinase signaling networks, are among the key 
signaling pathways involved in the regulation of organ size through their respective function in 
the controlling cell size and cell number (4) (Figure 2).  
 
Figure 1. Dendrogram of 491 
eukaryotic protein kinase 
domains from 478 genes. Major 
groups are labeled and colored. 
Taken from (2). 
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TOR was firstly identified in yeast as “Target Of the FKBP-Rapamycin complex” (short as 
“Target Of Rapamycin”) by Hall’s laboratory (5) and later on characterized as a master cell 
growth regulator (6, 7). The TOR kinase acts as a central signaling sensor by adjusting cellular 
metabolic output to match the energy status and growth factor availability. In a simple model, 
under nutrient rich condition, growth factors activates PI3K/PKD1/PKB (also known as AKT) 
signaling, activated PKB phosphorylates and inhibits TSC2 leading to the accumulation of Rheb-
GTP, which activates TOR (8, 9). Activated TOR stimulates cell growth and thus increases cell 
mass by coordinating signaling such as protein synthesis, ribosome biogenesis and proper cell 
cycle entry (6, 10). In the starvation condition, TOR activity is inhibited. Inactivated TOR 
restricts the cell metabolic activity and results in cell cycle block. Thus, TOR signaling is 
appreciated as a temporal and spatial regulator of cell growth (7). Hyperactivated TOR signaling 
results in increased cell growth and sometimes promotes some cells into cell cycle progression (7, 
10).  
 
Figure 2. Organ size control by the 
TOR and Hippo pathways. TOR 
pathway stimulates cell growth and 
thereby increases the cell size. The 
Hippo pathway regulates organ size by 
promoting cell proliferation and 
inhibiting cell death. Images adapted 
from (4).  
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1.2 The Hippo pathway 
The Hippo pathway is an emerging organ size control network by inhibiting cell proliferation 
and promoting cell death. The Hippo pathway was originally identified by Drosophila genetics 
with the discovery that the mutants represent overgrowth phenotype. The first Hippo component 
identified from the mosaic-based screens was named Warts (Wts, also called Lats) in 1995 (11, 
12), which encodes a kinase of the nuclear dbf-2-related (ndr) family (Figure 3). Wts was 
considered as an orphan tumor suppressor until 2002, when Salvador (Sav, also called Shar-pei) 
mutant was identified (Figure 3) (13, 14). Salvador encodes a WW domain-containing protein, 
and its mutations result in a similar cell-autonomous overgrowth as Wts mutant clones. 
Importantly, Tapon et al. demonstrated that Sav and Wts genetically and physically interacted 
with each other, suggesting that these two protein function in the same pathway (13). The 
breakthrough came in 2003 when 5 independent groups reported the finding of the Hippo 
mutants, which encodes a mammalian homolog of Ste20 family kinase MST1/MST2 (Figure 3) 
(15-19). Remarkably, Hippo kinase formed a complex with Sav and Wts, thus putting the three 
tumor suppressors together for the first time as the Salvador-Warts-Hippo pathway (15).  
 
 
 
 
Figure 3. Overgrowth phenotype of the Hippo pathway mutants. Images adapted from (11, 13, 15, 20)
Hippo lats 
 
mob1 
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In addition to Wts, the nuclear dbf-2-related family kinases, such as ndr kinases, are reported to 
regulate cell cycle progression and cell morphogenesis from yeast to man (21). The ndr family 
kinases are identified to function in a complex with an adaptor protein MOB (Mps one binder) 
(22, 23), raising the possibility that Wts might also bind to a fly mob. Lai et al. demonstrated this 
hypothesis by nicely showing that mutant of drosophila mats (Mob as tumor suppressor, also 
known as mob1) leads to the similar overgrowth phenotype in Hippo, Wts and Sav mutants 
(Figure 3) (20). Biochemically, Drosophila mob1 binds to Wts and bridges it to the upstream 
Hippo (24). This finding demonstrates that Mob1 is a bona fide key component of the Hippo 
pathway. 
Since Cyclin E and the cell death inhibitor Diap1 was observed to be increased in Wts and Sav 
mutants (15-19), which suggested Hippo downstream might be the transcriptional program 
related, researcher focused on the transcription factor related protein which interacts with LATS, 
searching for Hippo effectors. To this end, Pan’s Lab identified the Yorkie, a drosophila 
homolog of mammalian YAP and TAZ, from a yeast two-hybrid screening that binds to Lats 
kinase (25, 26). As yorkie is a transcriptional co-activator, a TEAD/TEF family transcription 
factor named Scalloped was found to form a complex with yorkie (27-30). Thus, yorki/Scalloped, 
YAP/TEAD and TAZ/TEAD in mammals, served as the downstream effector for the Hippo-
LATS signaling.       
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Taken together, these findings orchestrate a linear model for the canonical Hippo pathway (31).  
Mechanistically, the Hippo kinase (MST in mammals) forms a kinase cascade with the 
downstream Wts kinase (NDR/LATS in mammals), whereas Sav (SAV in mammals) and Mats 
(MOB in mammals) proteins function as positive co-activators. Classically, once activated by the 
Hippo/MST kinase, LATS kinase in turn phosphorylates the transcriptional co-activator 
YAP/TAZ and restrains its activity by preventing its nuclear translocation (32) and promoting its 
degradation (33)  (Figure 4) .  
The classical Hippo pathway control organ size by regulating the transcriptional program. As a 
transcription co-activator, YAP does not contain any DNA binding domain but functions through 
forming a complex with TEAD, whereby initiating the transcription of a subset of pro-survival 
genes. Recent findings further depicted the mechanism of YAP-TEAD interaction by showing 
that YAP competes the binding of TEAD to a default repressor VGLL4 (Tgi in Drosopholia) 
Figure 4. The core Hippo pathway.  
MST kinases in complex with SAV 
phosphorylates and activities MOB/LATS. 
LATS phosphorylates and deactivates 
YAP/TAZ. Intact YAP/TAZ forms 
transcriptional active complex with TEAD. 
Phosphorylated YAP/TAZ binds to 14-3-3 
resulting cytoplasmic retention and 
degradation.  
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(34-36). Once YAP/TAZ is phosphorylated by active Hippo signaling, they are restricted in 
cytoplasm and not able to enter nucleus to form the functional complex with TEAD.   
1.3 Regulation of the Hippo pathway  
Ever since the discovery of the Hippo pathway, one key issue in Hippo research is to identify its 
regulators. Using genetic models or biochemical approaches, many additional components have 
been identified to either modulate the core Hippo activity or interact with the Hippo effectors 
YAP/TAZ (Figure 5).   
Inactivation of YAP by activated Hippo signal was first observed in cell-cell contact condition 
(32), but the upstream activator was not known. The initial work identified two adaptor proteins 
Ex (Expaned) and FERM (4.1, Ezrin, Radxin, Moesin) domain protein Mer (Merlin, also known 
as NF2 for neurofibromatosis 2) (37). Later on, Kibra (a WW domain and C2 domain containing 
protein) was found to form a ternary complex with Mer and Ex (38-40). This complex activates 
the Hippo pathway through recruiting the Hippo/Sav/Wts (MST/SAV/LATS in mammals) to the 
membrane for activation (Figure 5A) (37-43). Recent findings further deciphered the mechanism 
for this activation process by showing that NF2 complex does not enhance the intrinsic activity 
of MST, but rather NF2 interacts with the N-terminus of LATS and thus facilitate the activation 
of LATS by MST1/SAV through the hydrophobic motif phosphorylation (44).  
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Apical-basal polarity components are revealed as another group of key players mediating the 
cell-cell contact induced Hippo signaling (Figure 5A). Apical-basal polarity network is 
orchestrated via the Crumbs (Crb) complex, the Par complex and the Scribble (Scrib) complex 
(Figure 5A). Crumbs (Crb) complex was delineated as an upstream regulator by interaction of 
Figure 5. Regulatory inputs of the Hippo pathway.  Regulation of the Hippo pathway by apical-basal 
polarity (A), PCP (B), mechanical cues and GPCR (C), and actin cytoskeleton (D). Arrowed or blunted ends 
indicate activation or inhibition, respectively. Dash lines indicate indirect or unknown mechanisms. Red 
lines in D represent actin filaments. Images taken from (45). 
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the intracellular FERM -binding motif (FBM) to Ex, thus altering the cellular location of Ex 
containing complex (46-50). The Par complex also regulates the Hippo pathway. Overexpression 
of atypical PKC (aPKC) induces activation of the Hippo effector Yorkie (49, 51). Drosophila 
epistatic interaction revealed that aPKC acts upstream of the Hippo pathway by changing the 
cellular location of RASSF and Hippo (49). However, the detail mechanism for this regulation is 
not fully understood yet. Recently, Par protein, MARK kinases in mammals, is also found to 
positively impact on the Hippo pathway through coordinating the Par/Scrib/MST/Sav complex 
(52-54). The Scrib complex was found to be a positive input for Hippo activity (55). Whilst Lgl 
acts antagonistically to aPKC to regulate Hippo and RASSF localization (49), the membrane 
located Scrib direct actives the Hippo pathway by scaffolding core kinase MST to the membrane 
for activation (55, 56). The Drosophila planar cell polarity complex also signals to the Hippo 
pathway (Figure 5B) (57-59) and this regulation is well reviewed in (60-62). 
Recent finding suggest that G protein couple receptors (GPCRs) also regulate the Hippo-YAP 
pathway (Figure 5C) (63-65). Several chemokines in the serum, such as LPA and S1P, were 
found to activate YAP/TAZ activity through GPCRs-RhoA GTPase (63, 65) mediated 
deactivation of LATS kinase (63). In the same report, several other diffusible ligand/factors, such 
as glucagon, epinephrine and dopamine were also identified as YAP/TAZ regulator through their 
corresponding GPCRs (63). Meanwhile, Thrombin also stimulates the YAP/TAZ activity 
through protease activated receptors (PARs) (64). Nevertheless, the mechanism how GPCRs are 
linked to RhoA GTPase and how RhoA-GTPase regulates LATS are not known yet. GPCR 
represents the largest family of plasma membrane receptors, which are able to be activated or 
blocked by a variety of ligands or pharmaceutical agents. Thus, the YAP/TAZ activity might be 
a fine-tuned readout by multiple GPCR signaling integration in a specified condition.    
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In addition, extracellular matrix induced cytoskeleton changes is another contributor to the 
regulation of the Hippo pathway (Figure 5D). Several reports demonstrate that YAP/TAZ as a 
sensor of machanotransduction in response to cell geometry changes (66-68), 
attachment/detachment (69) and stress fibers (66, 70). In general, mechanotransduction leads to a 
cellular morphology and cytoskeleton change, suggesting that cytoskeleton might be a signal 
integrator to the mechanical clues, which transduces further down to the Hippo pathway (71). 
Indeed, YAP/TAZ is regulated by F-actins, F-actin-capping/serving proteins and microtubules 
(66, 68, 70). RhoA is the major downstream of actin cytoskeleton in response to mechanical 
stresses. But how RhoA transduces to Hippo effector YAP/TAZ and whether the core kinase 
cascade is involved in RhoA-YAP/TAZ are still under debate and merit further investigation. 
1.4 MST/MOB/NDR core complex 
1.4.1 MST kinases 
MST kinases (sterile 20 like kinase, MST1/2) were firstly cloned as Ste20 like kinase and found 
to be activated under severe stress (72-74). Later on, MST1/2 kinases were identified as the 
mammalian Hippo kinase when Sav-Hippo-Wts pathway was discovered in Drosophila (15-19). 
Regulation and regulators of MST kinases 
MST1 contains an N-terminal kinase domain, followed by an auto-inhibitory domain and a C-
terminal protein-protein interaction domain called SARAH (Salvador-RASSF-Hippo) (75). In 
addition to mediating the signal integration from RASSF/SAV(15, 76, 77), the SARAH domain 
is also essential for the activation of MST kinases themselves by inter-dimerization 
(MST1/MST2, MST1/MST1, MST2/MST2) induced trans-phosphorylation (78-80).  
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In addition to signaling through the classical Hippo downstream LATS kinase regulating 
proliferation and apoptosis (26), MST kinases are pro-apoptotic kinase by themselves (79, 81-83). 
Under apoptotic conditions, activated MST kinases cross-talk with caspases, resulting in a 
proteolytic N terminus (81, 84). Cleaved N terminal of MST translocates into the nucleus (83) 
and phosphorylates H2B (85), FOXO3 (86), JNK (87-90)  and activates p53 family members (77, 
91, 92) to execute the biological functions.  
Several upstream regulators and kinases have been characterized for MST1 
activation/deactivation. As described above, while the Mer/Kibra/NF2 complex and the Crb and 
Scrib polarity complex activate the MST-LATS cascade activity via membrane recruiting, aPKC 
complex negatively regulates MST-LATS activation. Besides, TAOK1 positively regulates MST 
kinases activity by direct phosphorylation (93, 94). Homeodomain-interacting protein kinase was 
also found to regulate Hippo-dependent tissue growth probably by promoting the nuclear 
accumulation of YAP (95, 96).  In addition, C-ABL phosphorylates MST1 at Tyrosine 433, 
activates and stabilizes MST1 (97, 98). Activation of MST by GPCRs and cytoskeleton is still 
under debate as the results from difference groups were inconsistent (63, 65, 68, 99). Some other 
negative regulators include protein kinases such as PKB (100-105), JNK (87-90), Salt induced 
kinase (SIK) (106) and RAF-1(107-109), and phosphatase like PHLLP (110) and PP2A (111, 
112). PKB and JNK phosphorylate MST1 at Threonine 120/387 (100-103)  and Serine 82 (89), 
respectively, and inhibit the proteolytic activation of MST1 initiated apoptotic signaling. SIK 
phosphorylates Sav at Serine 413 and disrupts Sav mediated Hippo/Wts interaction (106). RAF-1 
inhibits MST2 activity through SARAH domain mediated protein-protein interaction and further 
recruits phosphatase to deactivate MST1. The mechanism of phosphatase, like PHLLP (110) and 
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PP2A (111, 112), to deactivate MST activity is via the catalytic nature of phosphatase by 
removing the phosphate group of Threonine 183/180 from MST1 or MST2, respectively.  
Tumor suppressive role of MST kinases    
The physiological roles of MST kinases are unrevealed using knock-out mouse models. MST 
kinases are essential for early embryonic development as MST1/2 double knock-out mice were 
dead at embryonic day 8.5 due to the growth retardation, failed placental development, defect 
vascular patterning and hematopoietic development (113-115). MST1 and MST2 function 
redundantly for embryonic development as MST1 or MST2 single deletion mice were viable, 
fertile and development normally. Conditional knock out models in liver, intestine, pancreas and 
heart suggest that MST1/2 is a bona fide essential regulator controlling cell proliferation, 
apoptosis and differentiation. The phenotypes are summarized in table 1. 
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Key role of MST1 in immune deficiency 
The murine Mst kinases are most peaked in lymphoid tissues (127). Mst1 kinase plays critical 
roles in T cell adhesion (128), migration (99, 127, 129, 130), survival (127, 131-133). Depletion 
Table 1. Phenotypes of the Mst1/2 conditional knockout mice (downloaded from (116)  and modified) 
Tissues Phenotypes Reference 
Liver 
Dramatic hepatocyte proliferation and hepatomegaly; Development of 
hepatocellular carcinoma and cholangiocarcinoma within 2 months. 
(26, 114, 
115, 117-
120)  
Intestine 
Intestinal hyperplasia; An expansion of stem-like undifferentiated 
cells; An almost complete absence of all secretory lineages; 
Development of the polypoid lesions and colonic adenomas within 3 
months old. 
(120-122)  
Pancreas 
A significantly decrease in pancreas mass; Acinar cell atrophy; 
Overabundance of ductal structures;  
Smaller islets with abnormal α/β cell ratios in pancreas 
(123, 124)  
Heart 
Expansion of trabecular and subcompact ventricular myocardial 
layers; Thickened ventricular walls, and enlarged ventricular 
chambers without a change in myocardial cell size. 
(125, 126) 
18 
 
of MST1 and MST2 does not have significant impact in the development of thymocyote. 
However, ablation of MST1 results in a dramatic decrease of peripheral CD4+ and CD8+ T cells 
and B220+ B cells (99, 127, 129, 130). Interestingly, although the total numbers of peripheral 
CD4+ and CD8+ T cells and CD62Lhi/CD44lo naïve T cells are decreased, the ratio of 
CD62Llow/CD44high effector/memory T cells are increased in MST null mice (127). Clinically, 
patients bearing loss of function mutations of MST1 have been reported with a primary 
immunodeficiency syndrome characterized as T cell lymphopenia, neutropenia, infection and 
autoimmune dysfunction (132, 133).  
Deletion of Mst1, or both of Mst1 and Mst2, impairs the thymocyte egress and induces an 
accumulation of mature single positive thymocytes in thymus and a decreased number of 
peripheral lymphocytes (99, 134). Mst1-null mice show defects in T cell adhesion, trafficking, 
and intranodal migration in vivo (130). Thymocytes egress is controlled by gradient of S1P and 
requires the activation of RAC and RhoA (135-137). MST null mature thymocytes show 
impaired sensitivity of RAC and RhoA activation (99). Biochemical studies further demonstrate 
that phosphorylation of MOB1 by MST1 is essential to enable MOB1 interact with and activate 
DOCK8 (99). These studies suggest MST1/MOB1/DOCK8 axis might be a critical signal 
mediator from the S1P to cytoskeleton changes (99). Recently, Mst1 has also been shown to be 
involve in LFA-1/ICAM-1-dependent high-velocity medullary migration and is required for 
migrating thymocytes to associate with rare populations of Aire+ ICAM-1hi medullary thymic 
epithelial cells , suggesting MST1 might be a key factor in regulating thymocytes self-antigen 
scanning in the medulla (138).  
Collectively, the mice phenotype and clinical observations have clearly suggested MST kinases 
are one of the critical genes essential for maintaining the immune homeostasis. 
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1.4.2 MOB proteins 
MOB proteins are small adaptor proteins without any enzymatic activity and are conserved from 
yeast to human. In yeast, mob proteins are reported to be essential for mitotic exit and septation 
initiation networks by regulating ndr kinases (22, 23). In Drosophila, Mats (MOB as tumor 
suppressor)/dMOB1 physically interacts with Wts and is necessary for Wts activity (20, 24). 
Importantly, human Mob1 could functionally rescue the phenotype resulting from loss of Mats, 
indicating that the function of MOB protein is evolutionally conserved (20). Murine Mob1 has 
been shown to be essential for embryogenesis. Mob1 null embryos have a defect in primitive 
endoderm formation (139). Mice with a single allele of mob1a or mob1b developed spontaneous 
tumors at 70 weeks in a broad range of tissues, confirming the tumor suppressive role of mob1 in 
mammalian system (139). The tumor suppressive function of MOB1 has further been validated 
by a keratinocyte specific double knock out model (139).   
The human genome encodes six MOB genes, namely hMOB1A/B, hMOB2 and hMOB3A/B/C 
(Figure 6) (140). Another closely related gene (Phocein) was found to be part of 
PP2A/Striatin/MST3 complex (141). Interestingly, whereas hMOB1A/B physically interact and 
activate all four human NDR/LATS kinases (142-144), hMOB2 specifically negative regulates 
NDR kinase activity by completing the binding of NDR kinase to hMOB1 (Figure 7) (140). 
Although hMOB3A/B/C show higher sequence similarity to hMOB1 than hMOB2, 
hMOB3A/B/C proteins do not interact with or (de)activate all four NDR/LATS kinases (140, 
145).  
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The roles of hMOB1 have been extensively characterized in tissue cultured system. hMOB1A/B 
proteins are essential for the functions of human NDR1/2 in apoptosis and centrosome 
duplication in a NDR binding dependent manner (146, 147). In addition to the association with 
NDR kinases, hMOB1A/B proteins also interact with human MST1/2, bridging NDR/LATS to 
the upstream MST kinases (148). Moreover, human MST1/2 kinases and the Drosophila Hippo 
kinase phosphorylate hMOB1A/B and Mats, respectively, thereby increasing MOB1/Mats 
protein affinity towards NDR/LATS or Wts kinase (148). Furthermore, Binding of NDR kinases 
to hMOB1A/B is reported to release the kinase from the auto-inhibitory status by the auto-
Figure 6. phylogenetic analysis of the MOB protein family. Phylogenetic relationships within the 
MOB protein family. Top: phylogenetic tree using Clustal W phylogenetic calculation based on the 
neighbour-joining method. Budding and fission yeast scMob1p and spMob1p, respectively, group 
together with dMOB1 and hMOB1A/B (MOB1 subgroup), while scMob2p and spMob2p fall into a 
group together with dMOB2 and hMOB2 (MOB2 subgroup). dMOB3 together with hMOB3A/B/C 
forms a third group (MOB3 subgroup). Bottom: display of primary sequence identities within human 
MOB protein family. Adapted from (145). 
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inhibitory segment (AIS) (142). In summary, current findings proposed a model of NDR 
activation, in which hMOB1A/B is phosphorylated by MST1/2 which results in efficient ternary 
complex formation of hMOB1/MST/NDR, which in turn facilitates the phosphorylation of 
NDR1/2 by MST kinases (Figure 7).  
 
 
Moreover, spatial relocalization seems to be another critical aspect in NDR kinase activation. 
Artificial targeting of hMOB1 or Mats proteins to the plasma membrane leads to rapid and 
robust activation of NDR/LATS kinase or Wts, respectively (24, 144). Direct membrane 
targeting of Trc kinase itself could also rescues the effect of trc mutant flies (24, 144). These 
observations indicate cellular membrane might be a key place for activation of NDR/LATS 
kinases. However, the mechanisms of NDR kinases being recruited to and activated at the 
plasma membrane by MOB1 remain to be elucidated.  
Recently, a correlation of loss of hMOB1 with pathological grade of human brain tumor has been 
explored (149). This finding suggest that proteolytic degradation of hMOB1 by the up-regulated 
Figure 7. The MST/hMOB/NDR complex. 
hMOB1 binds to both LATS and NDR. 
hMOB1 is phosphorylated by MST1/2 
which results in efficient ternary complex 
formation of hMOB1/MST/NDR. hMOB2 
specifically interacts with un-phosphorylated 
NDR kinases, which competes the binding 
of hMOB1 to NDR. hMOB3 does not 
interact with or (de)activate NDR/LATS. 
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ubiquitin ligase praja2 is a pathological triggers in the gliomagenesis (149). Taken together, all 
these findings point that hMOB1 a critical tumor suppressive adaptor by regulating downstream 
NDR/LATS activity. 
hMOB2 protein share approximately 37% sequence identity with hMOB1 (Figure 6) (140, 145). 
While hMOB1 proteins bind to both NDR and LATS kinases, hMOB2 only interacts with NDR 
kinases (Figure 7) (140). hMOB2 associates with NDR kinase through the N terminal region of 
hMOB1 binding motif (140). Therefore, it is reasonable to observe the competing binding 
between hMOB1 and hMOB2 towards NDR kinases. Interestingly, while hMOB1 was found to 
associate with activated NDR kinases, hMOB2 forms a complex with intact un-phosphorylated 
NDR kinases (140). This affinity preference indicates that hMOB2 restricts hMOB1 induced 
activation process of NDR kinases (Figure 7). However, the mechanism of interplay between 
hMOB2 and hMOB1 towards NDR activation remains to be depicted. One possible explanation 
is the subcellular location of hMOB2. hMOB1 proteins predominantly locate at cytoplasm, but 
hMOB2 is found to be accumulated in the nucleus. This alternation of subcellular localization of 
hMOB2 might block the membrane location and activation of NDR kinase by hMOB1. 
Nevertheless, the functions of hMOB2 merit further investigation. 
hMOB3A/B/C proteins are three distinct protein products from three different genes. hMOB3 
group proteins share about 50% amino acid identity with hMOB1 (Figure 6) (145). However, 
hMOB3A/B/C do not interact with or (de)activate NDR/LATS kinases. The biochemical roles 
and potential physiopathological roles of uncharacterized hMOB3 need to be deciphered.  
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Taken together, MOB proteins are essential regulators of NDR/LATS kinases. While MOB1 
proteins function as activators, the role for human MOB2 protein is a specific negative regulator 
for human NDR kinases. The function of the hMOB3A/B/C proteins has to be defined.  
 
1.4.3 NDR kinases  
Activation of NDR kinases 
The NDR kinases belong to the AGC group of serine/threonine kinases (150). Members of the 
NDR family are highly conserved throughout evolution and can be found in organisms such as S. 
cerevisiae (Dbf2p, Dbf20p and Cbk1p), S. pombe (Sid2p and Orb6p), C. elegans (SAX-1 and 
LATS) and D. melanogaster (Warts and Trc) as well as other fungi, plants and protozoans (21). 
The human genome encodes four NDR family kinases: NDR1 (STK38), NDR2 (STK38L), 
LATS1 and LATS2 (21). Genetic and biochemical studies showed that NDR kinases are crucial 
regulators of important functions such as mitosis, cytokinesis, cell polarity and morphogenesis, 
cell cycle progression, apoptosis, proliferation, centrosome duplication  (21, 151, 152).  
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The primary structure of NDR kinases is conserved from yeast to men (Figure 8) (21). All NDR 
kinases contain both typical characteristics of AGC kinases required for activation but are unique 
among the AGC group because they exhibit two distinct features only present in the NDR family: 
an N-terminal regulatory domain (NTR) also known as the S100B/hMOB1 association domain 
(SMA) and an insert of about 30-60 amino acids between subdomains VII and VIII of the kinase 
domain (Figure 8) (21). The NTR is responsible for the interaction with S100B and hMOB 
Figure 8. Primary structure of selected NDR kinases. Eight members of NDR family kinases from 
unicellular to multicellular organisms are shown (H.s. Homo sapiens, D.m. Drosophila melanogaster, C.e. 
Caenorhabditis elegans, A.t. Arabidopsis thaliana, T.b. Trypanosoma brucei). The N-terminal regulatory 
domain (NTR, grey), the kinase domain (green) with the activation segment (yellow) and the 
hydrophobic motif (brown) are shown. In addition, the auto-inhibitory sequence (red) and conserved 
phosphorylation sites (blue dots) are indicated. Taken from (21). 
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proteins (21). The NDR/LATS NTR contains a number of basic and hydrophobic residues which 
were shown to be critical for the binding to hMOB1A. Strikingly, mutating the positive charged 
area in NDR or negative charged residues in MOB1 abolished their interaction, suggesting that 
the NDR/MOB complex formation is based on electrostatic interactions (145).  
The 30-60 residues insert between kinase subdomains VII and VIII contains a stretch of 
positively charged residues. This basic residue containing motif precedes the activation segment 
and seems to inhibit NDR kinase activity as mutation of these residues to alanine leads to a 
significant increase in NDR1/2 kinase activity. Therefore, this motif is also referred to as an 
auto-inhibitory sequence (AIS) (21).  
All NDR kinases contain two regulatory phosphorylation sites: the hydrophobic motif (HM) 
phosphorylation site (Threonine 444 in human NDR1) and the activation segment (AS) (Serine 
281 in human NDR1). While the hydrophobic motif is phosphorylated by upstream MST kinases 
(146, 147, 153, 154), the activation segment (AS) phosphorylation is not targeted any upstream 
kinase but is regulated via autophosphorylation (152). Interestingly, a third phosphorylation site 
located at the NTR of NDR (Threonine 74 in NDR1) kinases was found to be important for fully 
activation of NDR kinase since mutating of this site to alanine reduces kinase activity and 
abolishes the binding to hMOB1 (155). However, whether this phosphorylation site has intrinsic 
impacts on kinase activity or whether the reduced activity is from loss of hMOB1 binding still 
need to be defined. 
As discussed before, MST kinases are upstream kinases responsible for the HM phosphorylation. 
However, MST kinases seem not to function in a redundant manner towards NDR 
phosphorylation in different cellular processes. For instance, MST1 kinase is the predominant 
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kinase responsible for the activation of NDR1/2 during centrosome duplication and Fas ligand 
induced apoptosis (146, 147), while for chromosome alignment during mitosis, the major player 
shifts to MST2 (156).  However, during cell cycle progression, MST3 kinases, but not MST1 or 
MST2, is essential for induction of NDR activation (154). In addition to MST kinases, the 
activation process of NDR kinases is also regulated by hMOB proteins as describe above and 
might require a subcellular localization change, such as membrane targeting. Furthermore, 
phosphatase such as PP2A could also deactivate NDR kinases (21). Both of HM and AS 
phosphorylation sites are targets of PP2A. Treatment with okadaic acid, a potent PP2A inhibitor, 
dramatically activates NDR kinases (153, 157). Furthermore, recombinant PP2A completely 
deactivates human NDR kinases (157). Nevertheless, how PP2A regulates NDR kinases 
underlying physiological processes still needs to be addressed. Another level of regulation of 
NDR kinase activity by scaffold protein Furry is still largely unknown (156).  
Biological functions of NDR kinases 
The function of NDR kinases was initially identified to be involved in cell division in yeast (21, 
151, 152). C.elegant NDR kinase SAX1 and Drosophila Wts and Trc was reported to regulates 
neurite outgrowth and dendritic tiling (151, 158, 159). The NDR family kinase Wts was 
identified as a tumor suppressors in Drosophila and later Wts homolog Lats was shown to act as 
a tumor suppressor in mice (11, 12, 160). The other NDR family kinase Trc in Drosopholia was 
identified as a critical regulator of epidermal outgrowth and dendritic tiling and branching (158, 
159). Since our work mainly related to NDR kinases but not LATS kinases, we are going to 
focus on the role of mammalian NDR kinases during the following discussion. 
The first biological role of NDR kinases was identified by Hergovich and colleagues by showing 
that NDR kinases regulates centrosome duplication (161). Further investigation indicated that 
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MST1/hMOB1/NDR forms a functional ternary complex regulating this process (147). 
Meanwhile, another study carried out in the Hemmings laboratory show that NDR kinases are 
activated by RASSF1A and MST1 during Fas ligand induced apoptosis (146). Further, the same 
lab performed another investigation examining the role of NDR kinase during cell cycle 
progression and unraveled a functional MST3/NDR/p21 axis regulating G1/S cell cycle 
transition (154, 162). Interestingly, NDR kinases could also regulate c-Myc stability, however, 
the mechanism in this regulation is not fully known.  NDR1/2 were also implicated in the 
alignment of chromosomes during mitosis (156).  The first in vivo role of NDR kinases came 
from the NDR1 whole body knock out model. Aged Ndr1 knock-out mice developed 
spontaneous T cell lymphoma, suggesting a critical role of NDR kinases in T cell hemostasis 
(163). Taken together, all these cell biology and in vivo studies suggest that NDR kinases are 
bona fide downstream targets of Hippo/MST kinases. The function of mammalian NDR1/2 
merits further investigation using in vivo models.   
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1.5 Gliomas 
Gliomas, the most common type of brain tumor, are originated from mature glial cells or less 
differentiated glial progenitor cells (Figure 9) (164). Based on their aggressive nature, gliomas 
are classified into 4 grades according to the World Health Organization (WHO). Compared with 
lower grades (I and II), high-grade (III and IV) tumors have a worse prognosis and display 
histological features such as nuclear atypia, increased proliferation, microvascular proliferation 
and necrosis (164).  
 
 
Glioblastoma multiforme (GBM) is the grade IV gliomas with a median survival of 
approximately 14 months after diagnosis (165). Approximately 90% of GBM arise de novo, 
while 10% originate from lower grade astrocytoma and are known as “secondary” GBM (166).  
1.5.1 Resistance of high grade gliomas  
Despite the benefits of surgical resection and the use of adjuvant radiochemotherapies, patients 
almost invariably succumb to recurrent widespread tumor growth (Figure 10) (167-169). Thus, 
Figure 9. The neuroglial lineage tree. 
Self-renewing, common progenitors are 
thought to produce committed neuronal and 
glial progenitors that eventually 
differentiate into mature neurons, astrocytes 
and oligodendrocytes. Although the precise 
cells of origin for diffuse glioma variants 
and medulloblastoma remain largely 
unknown, a selection of likely candidates 
for each (dashed arrows) is indicated. 
Taken from (164) 
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defining the mechanism of resistance of GBM cells and discovering further effective therapeutic 
targets are crucial medical goals.  
 
 
The key challenge with malignant gliomas is that tumor cells escaping surgical resection are able 
to survive and invade adjacent brain tissues, even under the stress of intensive 
radiochemotherapy. Indeed, DNA damage response was shown to enhance the capacity for 
therapy resistance and invasiveness of residual tumor cells (170, 171). However, the mechanisms 
underlying radio-resistance remain largely unknown. 
Another recent emerging concept of resistance comes from the glioma stem cells. Glioma stem 
cells or glioma initiating cells have characteristics of stem cells with the property of long-term 
self-renewal and the capacity to differentiate (172). Although it has been demonstrate that 
CD133- can give rise to CD133+ cells in vivo, CD133 is still the most frequently used marker to 
Figure 10. Axial T1-weighted post-contrast MRI sequences of a patient with glioblastoma. (A) At 
diagnosis an enhancing multifocal temporal and right parietoccipital tumor is seen. (B) The patient 
received combined chemo- and radiation-therapy and achieved a response. (C) The tumor recurred 2 
years after diagnosis in a diffusely infiltrating fashion and the patient died. Taken from (169). 
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identify glioma stem cells (173, 174). In addition to CD133, several other markers, such as 
SSEA-1, Nestin, Sox2 and Musashi-1 have been also used (170, 175, 176). The DNA damage 
checkpoint is preferentially activated in CD133+ tumor cells and it has been demonstrated 
radiation induced DNA damage is more efficiently repaired in CD133 positive cells than in 
negative cells (170). Indeed, inhibition of the checkpoint kinases Chk1 and Chk2 sensitizes 
glioma stem cells to radiation induced cell death, indicating that targeting the DNA damage 
checkpoint may improve the efficacy of radiotherapy in GBM (170). Nevertheless, deeper 
investigation of the biological nature of glioma stem cells will shed light on the development of 
high effective therapy for high grade gliomas. 
1.5.2  Current therapy for gliomas 
After diagnosis, patients usually firstly get surgical removal of tumors as much as possible (177). 
Fractionated focal radiotherapy is the standard treatment after resection or biopsy. Exclusive 
chemotherapy (usually Temozolomide, TMZ) has been proposed for elderly patients (177). 
Concomitant and adjuvant TMZ chemotherapy significantly improved median, 2- and 5- year 
survival, and is the current standard of care for patients with glioblastoma up to age 70 (168). 
Selecting patients likely to benefit from TMZ therapy has been suggested basing on the basis of 
the methyl-guanine methyl transferase (MGMT) gene promoter methylation  (178).  
Several potential therapeutic targets have been proposed based on the deregulated signaling 
pathways, which has led to the first generation of drugs that inhibit these pathways in clinical 
trials. These agents are classified into growth factor receptor inhibitors, intracellular signal 
transducer inhibitors and angiogenesis blockers. Of note, EGFR appears to be the most attractive 
candidate, which is overexpressed in over 40% of primary GBM (179). The EGFR gene with a 
deletion of exon 2-7 (EGFRvIII) is ligand-independent constitutively active and promotes cell 
31 
 
proliferation and survival in many cancer types (180-182). The PDGFR subtypes and PDGF 
isoforms are also overexpressed and hyperactivated in malignant gliomas (183). In addition, key 
component of signaling pathways such as Ras, PI3K, PKB, MAPK, mTOR have also been 
proposed as attractive targets (164, 165). Furthermore, given the high vascularization of GBM 
tumors, anti-angiogenic drugs blocking interactions between secreted pro-angiogenic inducers 
and the correspondence receptors are considered as alternative strategies (184). 
1.5.3  The Hippo pathway in malignant gliomas 
The Hippo pathway has been characterized as tumor suppressive signaling networks by 
antagonizing the pro-oncogenic effectors YAP/TAZ. Deregulation of Hippo signaling 
components, such as NF2, MST and LATS/NDR kinases, MOB1 proteins, as well as the 
downstream effectors YAP/TAZ, has been reported in numerous animal tumor models and 
human malignancies (185). Of note, several critical and potential components of the Hippo 
pathway, such as Mer, hMOB1, CD44, YAP and TAZ, have been described to be relevant to 
gliomagensis and will be discussed below. 
Mer (also known as NF2 for Neurofibromatosis 2) is a member of Band 4.1 superfamily of 
proteins, which links the transmembrane proteins to the actin cytoskeleton. Mutation of Mer has 
been found in several types of nervous system tumors. In addition to mutational inactivation of 
the NF2 gene in NF2-related tumors, mutation and loss of Mer has been reported in other types 
of cancers, including high grade gliomas (186). Mer is found to be downregulated in human 
malignant gliomas . Re-expression of functional Mer, but not loss of function mutant, inhibits the 
growth of human glioma cells and promotes apoptosis in vivo (186). A link between Mer to MST 
kinases signaling provides the mechanism for this phenotype, indicating Mer activates the tumor 
suppressive Hippo signaling.   
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hMOB1 is an adaptor protein that orchestrates the MST-LATS/NDR kinase cascade. hMOB1 
has been demonstrated as a tumor suppressor in both Drosophila and mammalian models (20, 
139) . The first clinical relevance came from the study identifying the downregulating of hMOB1 
in glioblastomas.  Upregulated RING ligase praja 2 ubiquitylates and degrades hMOB1, leading 
to the decreased protein level of hMOB1(149). This study links the ubiquitin proteasome system 
to the deregulated Hippo signaling in the progression of gliomas.        
CD44 is a major cell surface hyaluronan receptor that has been implicated in the progression of 
many types of cancers. In glioblastomas, CD44 is found to be highly upregulated with pro-
oncogenic function by promoting GBM growth and survival in vivo (187). Interestingly, Merlin 
has been reported to mediate contact inhibition through CD44 (188). Therefore, it is tempting to 
speculate that CD44 signals upstream of the mammalian Hippo pathway via Mer and 
antagonizes the stress induced activation of MST-LATS kinases in gliomas. 
As CD44 is well established cancer stem cell marker, it is tempting to speculate the roles of 
Hippo signaling in cancer stem cells. Indeed, TAZ, one of the hippo effectors, has been reported 
to confer cancer stem cell-related traits on breast cancer cells (56). Moreover, the hippo 
transducer TAZ has been found to be implicated in the differentiation of glioma stem cells as 
well (189, 190).  Compared with mesenchymal GBMs, where TAZ is highly expressed and active, 
TAZ expression is lower in proneural GBMs and lowere grade gliomas.  The expression pattern 
is associated with CpG island methylation status of the TAZ promoter. TAZ is functional 
essential for mesenchymal glioma stem cells as silencing of TAZ in mesenchymal glioma stem 
cells leads to decreased expression of mesenchymal markers, invasion, self-renewal and tumor 
formation. Interestingly, CD44 seems to be a transcriptional target of TAZ, suggesting a 
potential feedback loop between CD44 and TAZ (189). However, the parallel YAP is found to 
33 
 
be dispensable maintaining the mesenchymal glioma stem cells (189). Nevertheless, YAP is also 
highly upregulated in high grade gliomas and is required for cell proliferation in GBM tumor 
cells (191). 
Several investigations suggest general epigenetic hypermethylation of the promoters of RASSF 
(192), MST (193) and LATS (194) kinases in many cancer types, which result in decreased 
protein levels in tumors. Therefore, it is not surprise to speculate the similar pattern would occur 
in malignant gliomas as well. 
In general, the YAP/TAZ destructive Hippo signaling seems to be suppressed in gliomas, either 
by mutational loss of upstream positive input Mer, or by epigenetic silencing of core kinases, or 
by proteolytic degradation of key co-activator hMOB1, or by upregulation of upstream inhibitor 
CD44. Inhibition of Hippo signaling results with hyperactivation of the transcriptional co-
activator YAP/TAZ. Therapeutically, one would think restoring of functional tumor suppressive 
Hippo signal by blocking the upstream negative regulators or reinforcing the positive inputs. 
Alternatively, targeting the binding of YAP/TAZ to its transcriptional coactivator TEAD would 
be another general and effective approach. One small molecular Verteporfin (VP) tested by Duo-
Jia Pan’s Lab represents one promising example to targeting YAP/TEAD interaction by small 
inhibitors (195). It has been tested recently that introducing a default repressive VGL4 functional 
fragment blocks the YAP/TEAD or TAZ/TEAD complex, pointing towards alternative 
therapeutic strategy with pharmaceutical peptide (35).              
Taken together, current investigations strongly suggest that modulating the Hippo-YAP/TAZ 
pathway might represent a promising therapeutic strategy in malignant gliomas.   
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2. Scope of thesis 
The human genome encodes six MOB family members (hMOB1A, -1B, -2, -3A, -3B and -3C). 
While hMOB1A/B functions as an activator for MST-LATS/NDR kinase cascade, hMOB2 was 
found as a specific negative regulator of NDR kinase by competing the binding of hMOB1 to 
NDR kinase. Although hMOB3 share higher sequence identity to hMOB1 than hMOB2, hMOB3 
proteins do not interact or interfere the NDR kinases. Thus, the biochemical functions of 
hMOB3A/B/C are completely undefined. Additionally, hMOB3 mRNA levels seem to be 
deregulated in several pathological diseases, such as mantel cell lymphoma, colon cancer and 
amyotrophic lateral sclerosis. A previous microarray analysis carried out in the lab identified 
hMOB3A /B/C were deregulated in glioblastoma multiform (GBM) as well.  
In this thesis, we investigated the role of hMOB3 in GBM and found that total hMOB3 proteins 
are upregulated in GBM. Importantly, we observed a correlation of hMOB3A/B/C mRNA 
expression with clinical survival, suggesting hMOB3A/B/C being a potential prognostic 
biomarker. Additionally, we explored the biochemical function by analyzing the interaction of 
hMOB3 with the upstream MST kinase and found hMOB3 specifically interact with MST 
kinases upon apoptotic stimulation and under cell-cell contact condition. Moreover, we 
demonstrated that binding of hMOB3 to MST1 inhibits the apoptotic cleavage of MST1 in GBM 
cells. Taken together, our results indicate hMOB3 negatively regulates apoptotic MST1 signaling, 
suggesting modulating hMOB3 might represent a potential therapeutic approach in GBM.   
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3. Results 
The results obtained during course of my thesis are shown in the following manuscript. Parts of 
the text in the manuscripts were taken from the summary, introduction, scope of the thesis and 
general discussion of this thesis. The numbering of references and figures of the manuscript is 
separate to that from the introduction and general discussion meaning that the first reference and 
the first figure of each manuscript is numbered as “1”.  
hMOB3 inhibits apoptotic cleavage of MST1 in glioblastoma multiform  
This part of this result will be presented in the manuscript entitled “hMOB3 modulates apoptotic 
MST1 signaling and supports tumor growth in glioblastoma multiforme”. Currently it is 
published in Cancer Research.  
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Abstract: 21 
New therapeutic targets are needed that circumvent resistance in glioblastoma multiforme 22 
(GBM). Here we show that the uncharacterized adaptor protein human Msp One Binder 3 23 
(hMOB3) is upregulated in GBM. In a search for its biochemical function, we find that hMOB3 24 
specifically interacts with MST1 kinase in response to apoptotic stimuli and cell-cell contact. 25 
Moreover, hMOB3 negatively regulates apoptotic MST1 signaling in GBM cells by inhibiting 26 
the MST1 cleavage activation process. We also demonstrate that the physical interaction 27 
between hMOB3 and MST1 is essential for this regulation of MST1. Further, we show that 28 
hMOB3 sustains GBM cell growth at high cell density and promotes tumorigenesis in vivo. In 29 
summary, our results suggest hMOB3 as a potential therapeutic target for the treatment of 30 
malignant gliomas.       31 
 32 
Introduction 33 
Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain 34 
tumor, with a median survival of approximately 14 months after diagnosis. Despite the benefits 35 
of surgical resection and the use of adjuvant radiochemotherapies, patients almost invariably 36 
succumb to recurrent widespread tumor growth (1, 2). Thus, defining the mechanism of 37 
resistance of GBM cells and discovering further effective therapeutic targets are crucial medical 38 
goals.  39 
The Hippo pathway is an evolutionarily conserved tumor suppressive signal originally identified 40 
in Drosophila as a tumor suppressive signal (3-9). Deregulation of Hippo signaling components, 41 
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such as MST and LATS/NDR kinases, MOB1 proteins, as well as the downstream effector YAP, 42 
has been reported in numerous animal tumor models and human malignancies (10).  43 
MST1 (Sterile 20-like kinase 1), the mammalian homolog of the Hippo kinase, plays a critical 44 
role in regulating cellular apoptosis and proliferation (11-15). MST1 contains an N-terminal 45 
kinase domain, followed by an auto-inhibitory domain and a C-terminal protein-protein 46 
interaction domain called SARAH (Salvador-RASSF-Hippo) (16). In response to apoptotic 47 
stimuli, MST1 is activated by dimerization-mediated trans-phosphorylation and caspase-48 
mediated cleavage (17-20). Cleaved MST1 translocates from the cytoplasm into the nucleus and 49 
induces chromatin condensation by phosphorylation different targets (21-25). Although Akt and 50 
JNK have been reported to phosphorylate MST1 and modulate its cleavage (26-29), the 51 
regulation of apoptotic MST1 signaling has not been completely defined.  52 
MOB1 (Mps One Binder 1) proteins were first characterized in yeast, where they are essential 53 
components of mitotic exit and septation initiation networks (30, 31). Drosophila mob1/mats 54 
functions as a tumor suppressor by regulating the activation of the Warts kinase (32, 33). The 55 
mammalian genome encodes 6 MOB proteins through 6 different genes, namely MOB1A/B, 56 
MOB2 and MOB3A/B/C (34, 35). Mammalian Mob1A and Mob1B are essential for embryonic 57 
development and prevent tumorigenesis in a broad range of tissues via a mechanism similar to 58 
that reported in flies (36, 37). The function of human MOB1 has been characterized as a co-59 
activator of the MST-NDR/LATS kinase cascade (38, 39). Human MOB2 has been reported to 60 
restrict NDR kinase signaling (34). Although hMOB3 shares higher amino acid sequence 61 
identity (50%) with hMOB1 than hMOB2 (37%), it neither interacts with nor activates 62 
NDR/LATS kinases (34, 35). Its biochemical functions remain unknown. Therefore, the 63 
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molecular roles of hMOB3 in the context of the mammalian Hippo pathway merit further 64 
investigation. 65 
In the present study we have found that the previously uncharacterized hMOB3 is overexpressed 66 
in GBM. Biochemically, hMOB3 directly interacts with MST1 kinase in response to apoptotic 67 
stimuli and at high cell density. Functionally, hMOB3 negatively regulates MST1 cleavage 68 
during etoposide-induced apoptosis and attenuates the apoptotic response. Moreover, hMOB3 is 69 
required to sustain tumor cell proliferation and growth in vitro and in vivo. Taken together, our 70 
study reveals that hMOB3 restricts the crosstalk between MST1 and caspases during apoptosis 71 
and supports tumorigenesis in GBM suggesting hMOB3 as a potential target for GBM therapy. 72 
 73 
Materials and Methods 74 
Patients. Tissue samples of primary GBM and adjacent non-neoplastic brain were processed in 75 
accordance with the guidelines of the Ethical Committee of the University Hospital of Basel. 76 
Tumors were diagnosed and graded according to the World Health Organization (WHO) 77 
Classification of Tumors of the Nervous System (40). 78 
Cell culture, transfection, and stimulation. HEK293 cell line was obtained from American 79 
Type Culture Collection (ATCC). Glioma cell lines were described previously (41, 42).  All the 80 
cell lines in this study were confirmed with absence of mycoplasma contamination 81 
(MycoAlertTM, Lonza) and regularly authenticated by growth and morphological observations. 82 
HEK293 and glioma cell lines were maintained in Dulbecco's modified Eagle's medium 83 
supplemented with 10% fetal calf serum. Transfection of HEK293 and GBM cells were carried 84 
out using jetPEI (PolyPlus Transfections, Dietikon, Switzerland) and Lipofectamine 2000 85 
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(Invitrogen, CA, USA) according to the manufacturer's instructions, respectively. Apoptosis was 86 
induced as indicated in the figure legends. Okadaic acid was purchased from Alexis 87 
Biochemicals (Enzo Life Sciences, Lausen, Switzerland). Cyclohexylamine (CHX), actinomycin 88 
D and etoposide were obtained from Sigma (St Louis, MO, USA).  89 
Annexin V assay. Annexin V staining was performed according to the manufacturer's 90 
instructions (BD Bioscience) and analyzed by FACSCalibur. The results were from three 91 
independent experiments and presented as mean ± standard deviation. Statistical analysis is 92 
performed in Excel with two tailed-paired-student t test.  93 
Tumor Implantation: Aythymic Nude–Foxn1nu mice (Harlan, France) were maintained in 94 
Specific and Opportunistic Pathogen Free (SOPF) facility with food and water ad libitum.  95 
U87MG cells (8x105 in 200l DMEM:Matrigel(1:1 ratio)) were implanted into left flanks. 96 
Tumor diameters were regularly measured via caliper and tumor volumes calculated as follows:  97 
Volume = d2  D  /6, where d is shorter tumor diameter and D is longer tumor diameter.  All 98 
in-vivo experiments were performed under approved authorization within the Swiss Federal 99 
Animal Welfare Law. 100 
 101 
Results 102 
hMOB3 is overexpressed in human GBM 103 
In a previous study, we performed a microarray analysis of 30 human gliomas (41). Interestingly, 104 
the mRNA levels of uncharacterized hMOB3 family members were found to be deregulated in 105 
GBM. Of these, hMOB3A and hMOB3C expression were elevated while hMOB3B was 106 
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downregulated (Supplemental Figure 1A). hMOB3A/B/C are three unique genes located on 107 
different chromosomes. Given that the three hMOB3 isoforms hMO3A/B/C are about 80% 108 
identical (35), we set out to investigate the function of total hMOB3 protein in GBM, instead of 109 
analyzing each isoform separately. To this end, we generated a rabbit polyclonal antibody 110 
against total hMOB3 that recognizes hMOB3A/B/C proteins but not hMOB1 or hMOB2 111 
(Supplemental Figure 1B-C and 1E).  112 
Using this novel antibody, we determined the total hMOB3 protein levels in human GBM 113 
samples by Western blotting and found it to be upregulated in the majority of solid GBM tumor 114 
samples compared with non-neoplastic human brain tissue (Figure 1A). Immunohistochemical 115 
staining confirmed total hMOB3 protein upregulation in human glioblastomas (Figure 1B). 116 
Moreover, scoring of hMOB3 protein expression in 63 clinical GBM samples revealed that 71.4% 117 
(45/63) of tumors displayed either medium or high hMOB3 expression levels (Figure 1C and 118 
Supplemental Figure 1F). 119 
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 120 
Figure 1. hMOB3 is overexpressed in human GBM. (A) Western blotting analysis of GBM 121 
lysates and non-neoplastic brain tissues (N.B.) with an anti-hMOB3 antibody. Molecular weights 122 
are expressed in kilo-Daltons (kDa). (B) Representative immunohistochemistry images of non-123 
neoplastic brain tissue using an anti-hMOB3 antibody (left: white matter; right: grey matter) and 124 
various human GBM tumors (left: GBM with partly gemistocytic differentiation; middle: GBM 125 
with focal spindle-shaped cytomorphology; right: GBM with specific staining in the tumor 126 
(upper right) but not adjacent non-neoplastic tissue (lower left)). (C) Scoring of hMOB3 127 
immunohistochemical staining in 63 human GBM samples (0: negative; 1: low; 2: medium; 3: 128 
high). For representative images, see Supplemental Figure 1F. (D) Kaplan-Meier (KM) survival 129 
curves for hMOB3 expression taken from the Rembrandt database. Cut-off is a twofold change. 130 
P value is provided by the database using log-rank test. Curves represent all patients (blue), 131 
patients with upregulation of hMOB3 (red), downregulation (green), and intermediate expression 132 
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(yellow). N=patient numbers. (i) KM curve for hMOB3A. Pup- vs inter-<0.01; (ii) KM curve for 133 
hMOB3B. Pup- vs down-<0.01, Pup- vs inter-=0.15, Pdown- vs inter-<0.05; (iii) KM curve for hMOB3C. 134 
Pup- vs inter-<0.05. (E) (i) Density plot of hMOB3 isoforms expression levels. Displayed are the 135 
normalized expression values for hMOB3A/B/C where 0 represents the expression mean of all 136 
samples. (ii) Prognostic value of hMOB3B expression in the TCGA-Gene Expression 137 
(IlluminaHiSeq  data subset) database. KM survival curves for 25% of patients with highest 138 
(“Up”) versus lowest (“Down”) of hMOB3B expression levels. Pup- vs down-=0.05. A detailed 139 
description of data extraction and processing as well as statistical analysis is provided in the 140 
“Statistical analysis and Bioinformatics ” section  in the supplementary Materials and Methods. 141 
 142 
 143 
 144 
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Supplemental Figure 1. Upregulation of hMOB3 in GBM and characterization of hMOB3 145 
antibody and shRNAs. (A) mRNA expression of  hMOB3A/B/C in normal human brain (Brain), 146 
oligodendroglioma (Oligo), astrocytoma (Astro), and glioblastoma multiforme (GBM). (B) 147 
Characterization of a purified home-made hMOB3 antibody. Lysates of HEK293 cells 148 
overexpressing Myc-targeted hMOB1A, 2, 3A, 3B, 3C were immunoblotted. (C) 149 
Characterization of hMOB3A/B/C shRNA constructs. Lysates of HEK293 cells overexpressing 150 
Myc-tagged hMOB3A, B or C in combinations of shLuc control, shMOB3AC1#, shMOB3AC2#, 151 
shMOB3B1#, or shMOB3B2# were analyzed by immunoblotting. (D) Characterization of the 152 
knockdown efficiency of hMOB3 shRNA constructs. Lysates of U87MG cells transiently 153 
transfected with the indicated plasmids were analyzed by immunoblotting. (E) Characterization 154 
of the hMOB3 antibody in immunohistochemical conditions. Immunohistochemical staining 155 
images of stable (i) U87MG_shLacZ and (ii) U87MG_shMOB3 cells. (iii) The knockdown 156 
efficiency was demonstrated by immunoblotting. (F) Representative images of the 157 
immunohistochemical staining of hMOB3 in GBM used for quantification in Figure 1C. Level 0: 158 
negative; Level 1: low; Level 2: moderate; Level 3: high.   159 
 160 
To explore the potential prognostic value of hMOB3, we compared clinical outcome and 161 
hMOB3 gene expression using the Rembrandt database (43). In agreement with our finding of 162 
upregulation of hMOB3A and hMOB3C (Supplemental Figure 1A), we did not identify any 163 
sample with hMOB3A and hMOB3C downregulation in human GBM in Rembrandt dataset 164 
(data not shown). Because of limited GBM sample numbers, we extended our analysis from 165 
“GBM” to “all glioma”. In this dataset, we found a statistically significant correlation between 166 
poor survival and high mRNA expression of hMOB3A and hMOB3C (Figure 1D (i) and (iii)); 167 
the opposite was found for hMOB3B where low expression correlates with poor survival (Figure 168 
1D (ii)).   169 
Next, we sought to validate these clinical correlations using the online TCGA-Gene Expression 170 
database (44). A total of 167 patient samples with available hMOB3A/B/C mRNA expression 171 
and survival data were extracted (denoted IlluminaHiSeq data subset). Within these samples, we 172 
again observed highly variable expression of the hMOB3B gene but relatively stable hMOB3A 173 
and hMOB3C expression levels (Figure 1E (i)), suggesting frequent genetic or epigenetic 174 
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alterations in the hMOB3B genomic locus. We further generated Kaplan-Meier curves for 175 
differential hMOB3B gene expression from the same dataset (Figure 1E (ii)). Since records for 176 
normal human brain control tissue were not available, we followed the common strategy to 177 
define the top 25% of the samples with highest expression as “Up” and the  25% with lowest 178 
hMOB3B expression as “Down”. Based on these criteria, 50% survival of patients with low 179 
hMOB3B levels was reduced by 40% compared to patients with high hMOB3B levels (10 versus 180 
16.6 months). These findings indicate that downregulation of hMOB3B predicts poor survival, 181 
fully consistent with the results from the Rembrandt dataset.  182 
To investigate the discrepancy between upregulated total hMOB3 protein levels in human GBM 183 
and its variable prognostic values from the Rembrand and TCGA mRNA datasets, we studied the 184 
interplay within hMOB3 members by single knockdown of the most variable member, hMOB3B. 185 
Interestingly, upregulation of total hMOB3 protein in U373MG cells by specific knockdown of 186 
hMOB3B pointed towards compensatory mechanisms of hMOB3A/C and hMOB3B 187 
(Supplemental Figure 1D). Therefore, it appears that depletion of hMOB3B results in the 188 
upregulation of hMOB3A/C protein, which indicates that low levels of hMOB3B in GBM might 189 
result in high hMOB3A/C levels. This could potentially explain the observed association 190 
between poor survival and low hMOB3B expression (Figure 1D).   191 
Collectively, our analysis indicates that total hMOB3 is up-regulated at the protein level in GBM 192 
and that expression of hMOB3A/B/C is associated with clinical outcomes. Based on these 193 
findings it is tempting to speculate that total hMOB3 protein has proto-oncogenic properties.   194 
 195 
hMOB3 interacts with MST1 in response to apoptosis and high cell density 196 
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Unlike hMOB1 and hMOB2, hMOB3 does not bind to LATS and NDR kinases (34, 35). To 197 
investigate the involvement of hMOB3 in GBM, we asked whether hMOB3 plays a role in 198 
regulating the upstream Hippo kinase MST1. Since hMOB1 was reported to form a complex 199 
with MST1 and NDR1 upon apoptotic stimulation (38), we firstly analyzed the physical 200 
interaction between MST1 and hMOB3 under apoptotic conditions. To this end, we performed 201 
MBP pull-down assays using purified E. coli-expressed MBP-tagged hMOB3A as a bait to 202 
purify N terminal Flag-tagged MST1 from etoposide-treated HEK293 cells. Interestingly, 203 
hMOB3A interacted with MST1 in this experimental setting (Figure 2A). Consistently, 204 
endogenous MST1 could be co-immunoprecipitated by overexpressed hMOB3 in response to 205 
okadaic acid (Figure 2B, left panel) and vice versa (Figure 2B, right panel). However, although 206 
hMOB3 bound to MST1, hMOB3 did not interact with endogenous NDR/LATS (Supplemental 207 
Figure 2A). We next analyzed the interactions of MST1 with all hMOB3 members using purified 208 
MBP-tagged hMOB3 to pull down purified untagged human MST1 expressed in Sf9 insect cells. 209 
Consistently, untagged MST1 purified from Sf9 cells could be pulled down with MBP-210 
hMOB3A/B/C, excluding tag-mediated unspecific binding and illustrating that MST1 and 211 
hMOB3 interact directly (Figure 2C and Supplemental Figure E). However, to our surprise, the 212 
interaction between MST1 and hMOB3 in HEK293 cells was lost at low cell density (50%) 213 
without any stimulation (Figure 2B and 2D lane 1 and Supplemental Figure 2B). 214 
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 215 
Figure 2. hMOB3 interacts with MST1. (A) hMOB3A interacts with Flag-tagged MST1. After 216 
incubation of purified E.coli-expressed MBP or MBP-hMOB3A with etoposide-pretreated Flag-217 
tagged MST1 overexpression HEK293 cell lysates, complexes were analyzed via MBP pull-218 
down assay followed by immunoblotting. (B) Overexpressed hMOB3 interacts with endogenous 219 
MST1 upon okadaic acid (0.5nM) treatment (left panel) and vice versa (right panel). U87MG 220 
cell lysates overexpressing HA-tagged hMOB3 (left panel) or HA-tagged MST1 (right panel) 221 
with or without treatment were analyzed by immunoprecipitation (IP). Complexes and input 222 
lysates were assayed by immunoblotting. (C) hMOB3A/B/C interacts with MST1 directly. After 223 
incubation of purified E.coli-expressed MBP or MBP-hMOB3A/B/C with purified SF9-224 
expressed untagged MST1, the complexes were analyzed via MBP pull-down assay followed by 225 
immunoblotting. (D) hMOB3 interacts with MST1 upon stimulation of cell death and at high cell 226 
density. Lysates of HEK293 cells co-expressing HA-tagged MST1 and Flag-tagged hMOB3A 227 
were treated with the indicated reagents (Etoposide, 100µM; anti-Fas, 0.5 μg/ml, CHX, 15ug/ml; 228 
Actinomycin D  2μM; Okadaic Acid, 0.5nM ) at around 50% confluence or cultured to 100% 229 
confluence, and were analyzed by immunoprecipitation (IP). Complexes and input lysates were 230 
assayed by immunoblotting. (E) hMOB3 interacts with active MST1. After incubation of 231 
purified E.coli-expressed MBP-hMOB3A with untreated or okadaic acid (0.5nM) pretreated, 232 
etoposide (100µM) -pretreated or cell-cell contact-conditioned Flag-tagged MST1 233 
overexpressing HEK293 cell lysates, complexes were analyzed via MBP pull-down assay 234 
followed by immunoblotting.  235 
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We next asked whether the interaction of MST1 with hMOB3 occurs under general apoptotic 236 
stress. To address this question, we co-expressed hMOB3A with MST1 in HEK293 cells. Prior 237 
to immunoprecipitation, the cells were treated with various apoptotic stimuli or grown to 100% 238 
confluence. Strikingly, in contrast to low cell density without any treatment, hMOB3/MST1 239 
complex formation was induced by a broad range of apoptotic stimuli as well as by increased 240 
cell-cell contact due to high cell density (Figure 2D). To avoid artificial binding of two 241 
overexpressed proteins inside cells, we confirmed the interaction by in vitro pull-down using 242 
purified E.coli-expressed MBP-tagged hMOB3A as bait. Consistently, MST1 was only pulled 243 
down from stressed HEK293 cells (Figure 2E). In the reverse approach, hMOB3A was also 244 
immunoprecipitated by MST1 in HEK293 cells (Supplemental Figure 2D). 245 
To gain insight into the domains of MST1 responsible for binding to hMOB3, we generated a 246 
series of MST1 truncation mutants illustrated in Figure 3A. We tested the interaction between 247 
these mutants and wild-type hMOB3A by co-immunoprecipitation and found that the minimal 248 
fragment of MST1 required for binding of hMOB3 comprises the kinase domain and the auto-249 
inhibitory domain (Figure 3B and 3C). However, neither the kinase domain nor the auto-250 
inhibitory domain alone was sufficient for the association with hMOB3 (Figure 3B lane 7 and 3C 251 
lane 3). Notably, the SARAH domain was found to be dispensable for the interaction as SARAH 252 
domain deletion mutant showed similar affinity as the wild-type full-length MST1 (Figure 3B). 253 
A C-terminal MST1 fragment containing the auto-inhibitory domain and the SARAH domain 254 
also did not form a complex with hMOB3, further confirming that the SARAH domain is not 255 
involved in this binding (Figure 3C lane 2).  256 
Next, we asked whether the kinase activity of MST1 is required for its interaction with hMOB3. . 257 
As illustrated in Figure 3A, the regulation of MST1 activity requires the ATP-binding site Lys59 258 
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and the phosphorylation of Thr183 (20). Therefore, we investigated the interaction using two 259 
inactive MST1 mutants. Remarkably, the interaction between MST1 and hMOB3 was abolished 260 
when MST1 was mutated into an inactive form either by conversion of the ATP-binding site 261 
Lys59 to Arg or the phosphorylation site Thr183 to Ala (Figure 3B lane 5 and 3D lane 4). As 262 
expected, binding was restored when Thr183 was mutated to glutamic acid (Figure 3D lane 5). 263 
We also observed the binding of MST1T183E and hMOB3 at 50% cell density (Supplemental 264 
Figure 2F), further indicating that phosphorylation of threonine 183 is critical for the interaction. 265 
To further confirm the observation of activity of MST1 dependent interaction with hMOB3, we 266 
treated untagged MST1 purified from Sf9 cells with lambda-phosphatase to dephosphorylate 267 
MST1 prior to pull down experiments. Significantly, phosphatase treatment decreased binding of 268 
MST1 to hMOB3A (Figure 3E lane 3).  269 
Taken together, our analysis indicates that the interaction between MST1 and hMOB3 is induced 270 
by apoptosis and cell-cell contact stress and depends on MST1 phosphorylation and kinase 271 
activity, while the SARAH domain is dispensable.  272 
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 273 
Figure 3. hMOB3 binds to the active MST1 N-terminus kinase domain and auto-inhibitory 274 
domain. (A) Primary structure of wild-type MST1 and an overview of HA- or GFP-tagged 275 
mutant derivates. Amino acids Arg59 and Thr183 are the ATP-binding and auto-phosphorylation 276 
sites, respectively. Arg59 and Thr183 were mutated to Lys and Ala, respectively. K59R and T183A 277 
mutants are kinase dead. (B) Etoposide (100 µM) -pretreated or untreated lysates of HEK293 278 
cells containing the indicated combinations of HA-tagged MST1 forms and Flag-tagged 279 
hMOB3A (wild type) were analyzed by immunoprecipitation (IP). Complexes and input lysates 280 
were analyzed by immunoblotting. (C) Etoposide (100 µM) -pretreated HEK293 cell lysates co-281 
overexpressing the indicated combinations of GFP-tagged MST1 forms and Flag-tagged 282 
hMOB3A (wild type) were analyzed by immunoprecipitation (IP). Complexes and input lysates 283 
were analyzed by immunoblotting. (D) HEK293 cells overexpressing HA-tagged MST1 alone or 284 
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co-overexpressing the indicated combinations of HA-tagged MST1 forms and Flag-tagged 285 
hMOB3A (wt) were harvested and lysed at different cell confluences and the lysates analyzed by 286 
immunoprecipitation (IP). Complexes and input lysates were analyzed by immunoblotting. The 287 
T183E mutant is not constitutively active but functions similar to the wild type (20). (E) Purified 288 
SF9-expressed, untagged active wild-type MST1 was first treated with lambda phosphatase 289 
(PPase). Untreated or treated MST1 was then subjected to pull-down assay with purified E.coli-290 
expressed MBP or MBP-tagged hMOB3A. Complexes and input lysates were analyzed by 291 
immunoblotting. 292 
 293 
 294 
Supplemental Figure 2. hMOB3 specifically interacts with MST1. (A) hMOB3 and MST1 295 
form a complex without NDR or LATS kinases upon okadaic acid (0.5nM) treatment. Okadaic 296 
acid-treated lysates of HEK293 cells expressing HA-tagged MST1 alone or co-expressing HA-297 
tagged MST1 and Myc-tagged hMOB1A/2/3A/3B/3C were analyzed by immunoprecipitation 298 
(IP). Complexes and input lysates were assayed by immunoblotting. (B) hMOB3 does not bind 299 
to MST1 at low cell density without stimulation. HEK293 cells co-expressing HA-tagged MST1 300 
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and Flag-tagged GFP or hMOB3A/B/C were harvested at 50% confluence without any pre-301 
treatment and the lysates analyzed by immunoprecipitation (IP). Complexes and input lysates 302 
were assayed by immunoblotting. (C) High cell density induces the interaction between MST1 303 
and hMOB3. HEK293 cells co-expressing HA-tagged MST1 and Flag-tagged hMOB3A were 304 
harvested at the indicated confluences without pre-treatment. Lysates were analyzed by 305 
immunoprecipitation (IP). Complexes and input lysates were assayed by immunoblotting. (D) 306 
Binding of MST1 and hMOB3. Okadaic acid (0.5nM) -treated lysates of HEK293 cells 307 
expressing HA-tagged MST1 alone or co-expressing HA-tagged MST1 and Myc-tagged 308 
hMOB3A were analyzed by immunoprecipitation (IP) using an anti-HA antibody. Complexes 309 
and input lysates were assayed by immunoblotting. (E) High cell density induces the interaction 310 
between MST1/2 and hMOB3A/B/C. HEK293 cells co-expressing HA-tagged MST1/2 and 311 
Flag-tagged hMOB3A/B/C were harvested at cell-cell contact condition. Lysates were analyzed 312 
by immunoprecipitation (IP). Complexes and input lysates were assayed by immunoblotting. (F) 313 
Interaction between MST1 mutant and hMOB3. HEK293 cells co-expressing HA-tagged MST1-314 
T183E or wild type with Flag-tagged hMOB3A were harvested indicated culture confluence. 315 
Lysates were analyzed by immunoprecipitation (IP). Complexes and input lysates were assayed 316 
by immunoblotting.  317 
 318 
hMOB3 negatively regulates cleavage of MST1 in GBM cells 319 
Having demonstrated that hMOB3 is highly upregulated in GBM and that hMOB3 interacts with 320 
MST1, we next addressed the biological effect of hMOB3 on the activity of MST1 in GBM 321 
(Figure 4). The kinase domain and auto-inhibitory domain of active MST1 also interacts with 322 
caspases during apoptosis (17-21). Therefore we focused on the interplay of hMOB3, MST1 323 
cleavage and caspases in the cellular apoptotic response of GBM cells. To this end, we generated 324 
hMOB3-overexpressing U373MG cells and evaluated the apoptotic response to the standard 325 
chemotherapy drug etoposide. Notably, the cleavage of endogenous MST1 was reduced in 326 
hMOB3-overexpressing cells compared to control cells (Figure 4A). We next determined the 327 
biological consequences of hMOB3 overexpression by analyzing the apoptotic response. In 328 
agreement with decreased levels of cleaved MST1, overexpressed hMOB3 attenuated apoptosis, 329 
as reflected by decreased levels of cleaved poly (ADP-ribose) polymerase and caspase3 proteins 330 
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(Figure 4A). Furthermore, Annexin V staining revealed a decrease in apoptotic cells of 331 
approximately 40% in hMOB3A/B/C overexpressing cells upon etoposide treatment (Figure 4B).   332 
As cleaved MST1 translocates into nucleus (21), we next analyzed signaling downstream of 333 
MST1 cleavage. In the absence of a suitable immunofluorescence antibody to analyze the 334 
subcellular distribution of endogenous MST1, we performed subcellular fractionation assays to 335 
examine nuclear translocation of cleaved MST1 in etoposide treated cells. Consistent with a 336 
decrease in total levels of cleaved MST1, nuclear cleaved MST1 was also significantly reduced 337 
in hMOB3-overexpressing U373MG cells (Figure 4C). Histone H2B has been reported to be a 338 
key substrate mediating apoptotic MST1 signaling (24). We further analyzed H2B Ser14 339 
phosphorylation in response to etoposide and found a decrease in Ser14 phosphorylation in 340 
hMOB3B-overexpressing U373MG cells (Figure 4D).  341 
To further test our conclusions on the effect of endogenous hMOB3 on MST1 cleavage and 342 
apoptosis, and given the functional redundancy of hMOB3A/B/C (Figure 4A-B), we generated a 343 
construct containing two independent short hairpin RNAs targeting all hMOB3 isoforms 344 
(shRNA-MOB3 B2#AC1#, described in Supplementary Methods and Materials; Supplemental 345 
Figure 1C and 1D, hereafter referred shMOB3). We subsequently used this construct to generate 346 
tetracycline-inducible hMOB3 knockdown U373MG cells. Strikingly, etoposide induced MST1 347 
cleavage was higher after tetracycline-induced hMOB3 knockdown than in control cells without 348 
tetracycline treatment (Figure 4E). We observed a similar phenotype in three additional clones 349 
(Supplemental Figure 3A). To examine further whether hMOB3 attenuates apoptotic cleavage of 350 
MST1, we also generated stable knockdown cells in the U87MG and LN229 lines. Similar 351 
enhanced cleavage of MST1 and apoptosis was observed in stable hMOB3 knockdown U87MG 352 
and LN229 cells compared with U87MG_shLacZ or LN229_shLuc control cells, respectively 353 
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(Figure 4G and Supplemental Figure 3B). Moreover, Annexin V staining revealed an increase in 354 
apoptosis of approximately 1.8 fold and 1.6 fold in hMOB3 depleted U373MG and U87MG cells, 355 
respectively (Figure 4F and Figure 4H). Collectively, these data further support the notion that 356 
hMOB3 negatively regulates apoptotic cleavage of MST1 in GBM cells. 357 
To examine whether there is any correlation between hMOB3 protein levels and the apoptotic 358 
response in GBM cell lines, we treated ten glioma derived cell lines with etoposide for 24 hours 359 
before measuring MST1 cleavage and apoptosis markers (Supplemental Figure 3C). Based on 360 
their sensitivity to etoposide, we performed a Pearson correlation test and found a correlation 361 
coefficient of -0.6 between hMOB3 protein and cleaved MST1, indicative of a moderate 362 
negative correlation. Taken together, our data suggest that hMOB3 significantly contributes to 363 
modulate the sensitivity of GBM cells to the chemotherapeutic agent etoposide. 364 
55 
 
 365 
Figure 4. hMOB3 inhibits apoptotic MST1 cleavage. (A) U373MG cells stably expressing 366 
Myc-empty-vector (Myc EV) or Myc-tagged hMOB3A/B/C were treated with DMSO or 367 
etoposide (Etop, 100 µM) for 12 or 24 hours. Treated cells were harvested for immunoblotting. 368 
(B) In parallel, apoptosis after a 24 hours treatment was analyzed by FACS-based Annexin V 369 
staining. (C) U373MG cells overexpressing either empty vector (EV) or Myc-tagged hMOB3 370 
(hMOB3-Myc) were treated for 24 hours with etoposide (Etop, 100 µM), fractionated (lysate: 371 
total lysate; Cyto: cytoplasma; Nuc: nucleus), and processed for immunoblotting. (D) In parallel, 372 
pretreated and treated U373MG cell total lysates were analyzed by immunoblotting. (E) 373 
U373MG clone C4 cells stably expressing shRNA targeting all three hMOB3 isoforms in a 374 
tetracycline-inducible manner (U373MG Tet-ON shMOB3 C4) were treated with etoposide 375 
(Etop,100 µM) in the presence or absence of tetracycline (left panel). The untreated and 24 hours 376 
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treated cells were harvested for immunoblotting. (F) In parallel, apoptosis before and after 24 377 
hours etoposide treatment was analyzed by FACS-based Annexin V staining. (G) Pooled 378 
U87MG cells constitutively and stably expressing shRNA targeting E.coli LacZ or all three 379 
hMOB3 isoforms were treated with etoposide (Etop, 200 µM) (right panel). The untreated and 380 
24 hours treated cells were harvested for immunoblotting. (H) In parallel, apoptosis before and 381 
after 24 hours etoposide treatment was analyzed by FACS based Annexin V staining. 382 
 383 
 384 
Supplemental Figure 3. hMOB3 negatively regulates apoptotic MST1 cleavage. (A) Western 385 
blotting analysis of the effect of knockdown of hMOB3 on MST1 cleavage. Different U373MG 386 
Tet-ON shMOB3 or shLuc control clones were treated with 100µM etoposide (Etop) for 24 387 
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hours. Pretreated and treated lysates were analyzed by immunoblotting. (B) Effect of hMOB3 388 
knockdown in LN229 cells. LN229 shMOB3 or shLuc control cells were treated with 100µM 389 
etoposide (Etop) for the indicated times. The cells were harvested and lysed for immunoblotting. 390 
(C) Analysis of the response of in-house glioma cell lines to etoposide. The indicated cell lines 391 
were treated with 100µM etoposide for 24 hours, harvested, and lysed for immunoblotting.   392 
 393 
hMOB3 binding to MST1 is essential for hMOB3-mediated MST1 regulation 394 
We next examined the activity of hMOB3 on MST1 using MST1 binding-deficient hMOB3 395 
mutants. Since hMOB1 phosphorylation on Thr12 and Thr35 by MST1 is needed for 396 
MST1/hMOB1/LATS complex formation (11), we mutated Thr12 and Ser38 to alanines and 397 
tested the interaction with MST1 (Figure 5A). Surprisingly, we found that these two residues, 398 
which are conserved between hMOB3 and hMOB1 (34, 35), are dispensable for the 399 
hMOB3/MST1 interaction (Figure 5A). Therefore, based on the structure of hMOB1A (45), we 400 
generated a series of mutations in residues potentially critical for this interaction. Significantly, 401 
we found that Arg108/Lys109 in hMOB3A, which are conserved among hMOB3A/B/C 402 
(Lys107/Lys108 and Arg107/Arg108 for hMOB3B and hMOB3C, respectively), are critical residues, 403 
since hMOB3/MST1 complex formation was completely abolished by mutating both residues to 404 
glutamic acid (Figure 5A). We used the R108K109EE mutant to generate U373MG cells stably 405 
expressing binding-deficient mutant hMOB3A (Figure 5B). Cleavage of MST1 and apoptotic 406 
responses were analyzed in control, hMOB3A wild-type and hMOB3A binding deficient cells 407 
upon etoposide treatment. Significantly, MST1 cleavage and caspase3 activation were reduced in 408 
wild-type hMOB3A overexpressing cells but not in cells overexpressing the MST1 binding-409 
deficient mutant (Figure 5B). Quantification of Annexin V positive cells confirmed a decrease in 410 
apoptosis of 48% in U373MG cells overexpressing wild-type hMOB3, while cells expressing the 411 
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MST1 binding deficient mutant were affected by etoposide to a similar level as controls (Figure 412 
5C).  413 
Furthermore, we rescued the U87MG hMOB3 knock-down cells with wild type or MST1 414 
binding mutant hMOB3A and analyzed their apoptotic response to etoposide (Figure 5D-E). 415 
Indeed, apoptotic response (Figure 5D-E) was only rescued by wild type hMOB3A but not the 416 
binding deficient mutant. 417 
Taken together, our results strongly suggest that hMOB3 restricts MST1 apoptotic signaling via 418 
a direct physical interaction.  419 
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 420 
Figure 5. Binding capacity of hMOB3 is essential for its inhibitory effect on apoptotic 421 
MST1 cleavage. (A) Generation and characterization of an MST1 binding-deficient mutant. 422 
Glu55， Arg108Lys109，His165 and Thr15/Ser38 were mutated to Lys55, Glu108Glu109, Ala165 and 423 
Ala15/Ala38, respectively. Lysates of etoposide-treated or untreated HEK293 cells containing the 424 
indicated combinations of HA-tagged full-length wild-type MST1 and Flag-tagged hMOB3A 425 
forms were analyzed by immunoprecipitation (IP). Complexes and input lysates were analyzed 426 
by immunoblotting. (B) U373MG cells stably expressing the Myc-empty-vector (Myc EV) or 427 
Myc-tagged wild-type hMOB3A or the Myc-tagged R108E/K109E (RKEE) mutant were treated 428 
with etoposide (Etop, 100µM) for 12 or 24 hours. Treated cells were harvested for 429 
immunoblotting. (C) In parallel, apoptosis after 24 hours treatment was analyzed by FACS-based 430 
Annexin V staining.(D) U87MG_shMOB3 cells stably expressing the Myc-empty-vector (Myc 431 
EV) or Myc-tagged wild-type rescue hMOB3A or the Myc-tagged rescue R108E/K109E (RKEE) 432 
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mutant were treated with etoposide (Etop, 200µM) for 24 hours. Treated cells were harvested for 433 
immunoblotting. (E) In parallel, apoptosis after 24 hours treatment was analyzed by FACS-based 434 
Annexin V staining. 435 
 436 
hMOB3 sustains cancer cell proliferation and tumor growth 437 
We found that hMOB3 protein levels are increased in human GBM samples (Figure 1A and 1B) 438 
and hMOB3 interacts with MST1 under high cell density (Figure 2D and 2E). To investigate 439 
whether hMOB3 contributes to cancer cell proliferation in vitro and tumorigenesis in vivo, we 440 
analyzed cell proliferation upon tetracycline-inducible hMOB3 knockdown in U373MG cells. 441 
Knockdown of hMOB3 did not alter cell proliferation at low density up to day 2. However, from 442 
day 4 onwards, when cells started to form cell-cell contacts, knockdown of hMOB3 443 
progressively led to a drop in cell proliferation, with a maximum of 32% reduction at day 8 444 
(Figure 6A). Cell viability measurements indicated that the reduction in cell number was not due 445 
to apoptosis (data not shown). End-point MTT assays indicated a decline in cell growth of 446 
approximately 40% (Figure 6B). We next investigated the involvement of hMOB3 in 447 
tumorigenesis in vivo using a mouse xenograft model. As our standard U373MG flank tumor 448 
model did not yield tumors after 6 months (data not shown), we established a flank tumor model 449 
using constitutively hMOB3 depleted  U87MG cells as defined in Figure 4G. While the shLacZ 450 
control cells started to form palpable tumors after approximately 8 weeks, MOB3 knockdown 451 
cells showed negligible growth in vivo up to 14 weeks (Figure 6C). Tumor weight analysis at 452 
week 15 further confirmed that hMOB3 is essential for tumor growth (Figure 6D). Collectively, 453 
our U87MG cell based flank tumor model suggests that hMOB3 is required for GBM cell growth 454 
in vivo. In summary, our findings suggest that hMOB3 supports tumor cell growth in vitro and in 455 
vivo. 456 
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 457 
Figure 6. hMOB3 sustains tumor cell growth in vitro and in vivo. (A) Growth curve of pooled 458 
U373MG Tet_ON shMOB3 cells (C1/C4/C6) in the absence or presence of tetracycline. 459 
Depletion of hMOB3 was achieved by addition of 2 µg/ml tetracycline for 96 h.  (B) End-point 460 
MTT analysis of U373MG Tet_ON shMOB3 cells in the absence or presence of tetracycline. (C) 461 
Growth curves of flank tumors derived from constitutively hMOB3-depleted U87MG cells 462 
(U87MG_shMOB3) versus U87MG_shLacZ cells in vivo. Tumor volumes (cm3) were measured 463 
and plotted. (D) Tumors weight (g) derived from U87MG_shLacZ and U87MG_shMOB3 cells 464 
were measured and plotted. 465 
 466 
Discussion 467 
Genetic profiling has greatly advanced our understanding of molecular mechanisms underlying 468 
tumorigenesis and drug resistance. Based on microarray analysis of malignant gliomas, we 469 
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recently identified Mnk1 and MerTK as potential therapeutic targets for the treatment of GBM 470 
(41, 42). In the present study, we have discovered that the previously uncharacterized adaptor 471 
protein hMOB3A/B/C is deregulated in GBM (Figure 1). Of note, we found that hMOB3A and 472 
hMOB3C were increased at the mRNA level (Supplemental figure 1A). Consistent with our 473 
findings, data obtained from the Rembrandt database also showed upregulation of hMOB3A and 474 
hMOB3C in human GBM samples (Figure 1D); conversely, hMOB3B appears to be 475 
downregulated. The chromosome locus 9p21, on which the hMOB3B and IFNK genes are 476 
located, is frequently deleted (52%) or epigenetically inactivated in GBM (46-48), which might 477 
explain the varying mRNA levels of hMOB3B in our array and the publicly available Rembrandt 478 
and TCGA datasets. Importantly, we found that total hMOB3 protein levels were prominently 479 
upregulated in human GBM samples (Figure 1A, 1B and 1C), suggesting possible oncogenic 480 
properties of hMOB3 protein in GBM. Consistently, hMOB3A/C upregulation correlated with 481 
unfavorable clinical outcomes in the Rembrandt database, also pointing towards a potential 482 
proto-oncogenic function of hMOB3. In an attempt to reconcile the converse de-regulation of the 483 
respective hMOB3 isoforms in GBM, we found that knockdown of hMOB3B resulted in an 484 
upregulation of total hMOB3 protein levels (Supplemental Figure 1D). This suggests that, in 485 
response to inactivation of hMOB3B, compensatory upregulation of hMOB3A and C might 486 
provide GBM cells with increased oncogenic potential.  However, the basis of the compensation 487 
mechanisms is currently unknown and requires further analysis. 488 
While the role of hMOB1 protein has already been studied in tissue cultured cells and recently 489 
confirmed in a knock-out mouse model (36, 38, 39), the function of hMOB3 protein remained 490 
unknown. In a previous study we found that hMOB3 does not interact with NDR or LATS (34), 491 
but did not address MST1 as a potential interaction partner. As hMOB1 interacts with hMOB1, 492 
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we asked whether hMOB3 might do so as well. Indeed, we observed that all three hMOB3 493 
isoforms directly interact with mammalian Hippo, MST1 (Figure 2). Importantly, the 494 
hMOB3/MST1 interaction is induced by apoptosis and high cell density. Moreover, MST1 495 
kinase activity is required for the interaction (Figure 3B, 3D and 3E). MST1 kinase activity is 496 
regulated by various mechanisms (16), importantly by binding to SAV, RASSAF or to itself via 497 
the SARAH domain . Interestingly, the SARAH domain of MST1 is dispensable for hMOB3 498 
binding (Figure 3B and 3C), suggesting a different mode of their interaction rather than classical 499 
SARAH mediated signaling integration.  500 
MST1 is a well-characterized pro-apoptotic kinase that potentiates apoptosis by cross-talking 501 
with caspases and regulating downstream substrates (18, 19). Significantly, our observations 502 
suggest that hMOB3 regulates the cleavage process of MST1, which potentiates the apoptotic 503 
activity of the kinase (19). Overexpression of hMOB3 restricts MST1 cleavage and protects 504 
against the induction of apoptosis. Conversely, depletion of hMOB3 in GBM cell lines reduces 505 
MST1 cleavage and sensitizes cells to apoptosis induction (Figure 4). Importantly, we 506 
demonstrate that the protective effect of hMOB3 critically depends on its direct binding to MST1, 507 
since MST1-binding deficient mutant did not protect against apoptosis induction (Figure 5). This 508 
anti-apoptotic property of hMOB3 is likely to confer a considerable survival benefit to brain 509 
tumor cells, particularly if exposed to chemotherapeutic agents such as etoposide. A 510 
comprehensive recent meta-analysis revealed that etoposide treatment significantly improves 511 
overall survival in high grade gliomas (49). Our data suggest that concomitantly blocking the 512 
interaction between hMOB3 and MST1 might further increase the therapeutic benefit of 513 
etoposide. 514 
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Tumor cells tend to have a proliferative advantage over the surrounding non-neoplastic cells. We 515 
also find that hMOB3 significantly contributes to the proliferation rate of GBM cells (Figure 6A 516 
and 6B), further supporting its potential role as an onco-protein. Importantly, we confirm this 517 
observation in a xenograft model in vivo where depletion of hMOB3 suppresses tumor growth 518 
(Figure 6C and 6D).  519 
Taken together, our results characterize hMOB3 as a potential biomarker with clinical prognostic 520 
value for GBM. Negative regulation of the apoptotic cleavage of MST1 signaling by hMOB3 521 
improved cellular survival in response to the standard chemotherapeutic agent etoposide. In our 522 
study, targeting hMOB3 sensitized GBM cells to etoposide and blocked tumor cell growth. Thus, 523 
hMOB3 manipulation warrants further in depth analysis as it may represent a promising 524 
therapeutic strategy to target GBM.  525 
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 Supplementary Information 663 
Supplementary Materials and Methods 664 
Antibodies. Anti-myc 9E10, anti-HA 12CA5 and 42F13, and anti-α-tubulin YL1/2 were used as 665 
hybridoma supernatants. Anti-HA antibody (Y-11) and anti-β-actin were purchased from Santa 666 
71 
 
Cruz (CA, USA), and anti-Fas (CH-11) from Millipore (Zug, Switzerland). Anti-MST1, anti-667 
phospho-MST1/2, anti-cleaved caspase3, and anti-phospho-H2B Ser14 antibodies were 668 
purchased from Cell Signaling (Beverly, MA, USA) and anti-cleaved poly(ADP-ribose) 669 
polymerase (PARP) from BD Bioscience (San Jose, CA, USA). Anti-Flag antibody (M2) was 670 
obtained from Sigma. Anti-hMOB3 antibody was raised against full length MBP-tagged 671 
hMOB3A and affinity purified. 672 
Construction of plasmids. hMOB1, hMOB2, hMOB3A/BC, MST1 constructs have been 673 
described previously (34, 39). Mutants of MST1 and hMOB3 were generated by site-directed 674 
mutagenesis according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA). 675 
Truncation mutants of MST1 were cloned via PCR with BamH1 and XhoI sites. To generate an 676 
shRNA vector that simultaneously targets all three hMOB3A/B/C isoforms, termed 677 
pTERshMOB3, two independent oligonucleotide pairs, one targeting hMOB3A/C and the other 678 
hMOB3B, were cloned stepwise into the pTER vector as described before (38). The targeting 679 
sequences used were: 5′-  GCTACAAGCACTTCTACTA -3′ for hMOB3A/C, 5′- 680 
CAGGATGATCTCAAGTATA -3′, 5′- GAGGTTTGAGCTGCACAAA -3′ for hMOB3B, and 681 
5′- GACTACACAAATCAGCGATT -3′ for LacZ. Generation of the pTERshLuc control vector 682 
has been described previously (39). All constructs were confirmed by sequence analysis. 683 
Generation of stable cell lines. To generate inducible U373MG cell lines, U373MG were 684 
transfected with pCDNA6/TR (Invitrogen) and pTERshMOB3. Cells were selected in the 685 
presence of 100 ug/ml blasticidine (Invivogen, Toulouse, France) and 400 μg/ml Zeocin 686 
(Invivogen). Induction of shMOB3 was achieved by addition of 2 µg/ml tetracycline for 96 h. To 687 
generate stable knockdown cell lines, LN229 and U87MG cells were transfected with the 688 
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pTERshMOB3 construct. Cells were selected in the presence of 400 μg/ml zeocin 689 
(LN229_shMOB3 and U87MG_shMOB3). 690 
Immunoprecipitation, pull-down and fractionation of cells. Immunoprecipitation experiments 691 
were performed as described previously (34). Pull-down assays were performed in pull-down 692 
buffer (20 mM HEPES, 50 mM β-glycerophosphate, 100 mM NaCl, 10 mM NaF, 1 mM 693 
Na3VO4, 0.5% TX-100 at pH 7.4) supplemented with Roche protease inhibitor cocktail (Basel, 694 
Switzerland). Cytosolic and nuclear proteins were separated as described previously (34). 695 
Immunohistochemistry. Staining was performed with the Discovery XT machine (Ventana 696 
Medical Systems Inc., Tucson, Egg/ZH, Switzerland, AZ, USA). Haematoxylin-counterstained 697 
sections were photographed (Nikon, YTHM) and analyzed using ImageAccess Enterprise7 698 
software (Glattbrugg, Switzerland).  699 
Statistical analysis and Bioinformatics. Figure 1E-Survival analysis and differences in 700 
expression values were analyzed with help of the R/Bioconductor Survival analysis is based on 701 
the preprocessed GBM Deep-Sequencing datasets from  TCGA (TCGA GBM HiSeqV2 702 
version:2013-04-22). Correction for batch effects could be excluded, following the suggestions 703 
stated in the documentation of the 'TCGA Batch Effects Tool' 704 
(http://bioinformatics.mdanderson.org/main/TCGABatchEffects:Overview). Samples with 705 
missing information were excluded from the datasets. The datasets do not include 'normal tissue 706 
controls'. Hence, the provided preprocessed expression values of the hMOB3-genes were each 707 
normalized to the overall median of the cognate's isoforms expression values in all samples. 708 
Samples with expression values greater than or equal to the upper quartile were considered 709 
upregulated, such with expression values lesser than or equal to the lower quartile were 710 
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considered downregulated. Kaplan-Meier estimates were calculated based on the samples 711 
displaying up- or downregulation. Curves were compared applying a Peto and Peto modified 712 
Gehan-Wilcoxon test (http://CRAN.R‐project.org/package=survival). 713 
mRNA expression analysis(supplemental figure 1A). Preprocessed expression values where 714 
derived as described in (41). Statistical significance of the differences in expression values 715 
between samples was tested by Welch Two Sample t-tests. 716 
 717 
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4. General discussion 
Ever since the discovery of the Hippo pathway, enormous effort in Hippo research is to identify 
its regulators. Human MOB proteins are small essential adaptor protein bridging NDR/LATS 
kinases to the upstream MST kinases. Previous studies from the lab demonstrated hMOB1 
recruits NDR kinases to the membrane for activation and plays vital roles in the 
MST/hMOB1/NDR signaling complex (145). The hMOB2 was characterized as a NDR kinase 
specific negative regulator by competing the activation of NDR kinase by hMOB1 (140). 
Although hMOB3 shares higher amino acid identity (50%) with hMOB1 than hMOB2 (37%), 
hMOB3 was found to not interact with or (de)activate NDR/LATS. Thus the biochemical 
function of hMOB3 remains unknown (145). 
This thesis was aiming to investigate the function of uncharacterized human MOB3 proteins in 
the context of the Hippo pathway. To investigate the involvement of hMOB3 in the Hippo 
pathway, in the present study, we analyzed the protein-protein interaction of hMOB3 to the 
upstream MST kinases. Interestingly, we did not observe any interaction between hMOB3 with 
MST1 under normal low cell density tissue culture condition. But we found an induced binding 
of hMOB3 and MST1 upon apoptotic stimulations or under cell-cell contact stress. We next 
investigated the functional interplay between hMOB3 and MST1 focusing on the proteolytic 
process of MST1 based on the domains of MST1 essential for binding to hMOB3 and found that 
hMOB3 negatively regulates caspase mediated MST1 cleavage.  
Furthermore, we extended our investigation to analyze the potential pathological roles of 
hMOB3. A previous glioblastoma transcriptome screen carried out in the lab indicated all three 
hMOB3 isoforms were deregulated. Therefore, we focused on examining the pathological role of 
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hMOB3 in GBM. Indeed, we observed a correlation of worse survival and hMOB3A/C high 
expression group from public available Rembrandt database. Interestingly, the opposite 
correlation, meaning unfavorable survival was explored with hMOB3B low expression, from 
both Rembrandt and TCGA databases. A further analysis of hMOB3 isoforms suggested a 
compensatory mechanism between all three isoforms at the post-transcriptional level. Single 
knock-down of the most variable hMOB3B resulted in an up-regulation of total hMOB3 at 
protein level. Thus, our observations indicated that hMOB3 protein has certain pro-oncogenic 
functions in GBM. Indeed, from the GBM tumor lysates we observed a highly up-regulation of 
hMOB3 total protein compared with non-neoplastic brain. Immunohistochemistry staining 
further confirmed approximately 70% GBM tumor with moderate or high hMOB3 expression. 
The oncogenic function of hMOB3 was further validated by a U87MG derived flank tumor by 
showing that depletion of hMOB3 delays the flank tumor onset.             
Alternations in the expression profile of hMOB3 members have also been reported in colon 
cancer (196), mantle cell lymphoma (197, 198) and amyotrophic lateral sclerosis (ALS) (199, 
200). Importantly, hMOB3B is found to be down-regulated via chromosome locus deletion in all 
four diseases. However, whether deletion of hMOB3B locus is instructive or permissive to the 
disease onset is not fully known yet. Additionally, because of the general pattern of down-
regulation of hMOB3B and decreased hMOB3B correlated with inferior survival in colon cancer, 
mantle cell lymphoma and GBM, one would speculate specific function of hMOB3B out of 
hMOB3A/B/C family members. However, single knock down hMOB3B in HEK and 
glioblastoma cell lines resulted in an increased of total hMOB3 protein, suggesting 
compensatory mechanisms of hMOB3A/C and hMOB3B. Therefore, it appears that depletion of 
hMOB3B results in the upregulation of hMOB3A/C protein, which indicates that low levels of 
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hMOB3B might result in high hMOB3A/C protein levels. This might explain the observed 
upregulation of total hMOB3 protein in GBM.  Given an approximately 80% sequence identity 
across the whole protein but not specific domains, one would speculate that hMOB3A/B/C 
function redundantly at the protein levels. Indeed, our result demonstrated that hMOB3A/B/C 
protein functions redundantly and all three isoforms could impair the apoptotic cleavage of 
MST1 in glioblastomas. Hence, it is critical to evaluate the total hMOB3 at the protein level in 
the reported human tumors with hMOB3B downregulation to further clarify the expression of 
total hMOB3 at protein level. 
hMOB3 is found to regulate the cleavage of MST1 by direct protein- protein interaction under 
apoptosis in glioblastomas. Importantly, hMOB3 could also bind to MST1 at high cell density. 
We have investigated the expression pattern of mMOB3 in different mouse tissues. Significantly, 
mMOB3 proteins are highly abundant in spleen, thymus, lymph node and colon, but expressed at 
very low level in liver and small intestine (data unpublished). Interestingly, the cleavage of 
MST1 in liver and small intestine is significantly higher than other organs. The inverse 
correlation in mice tissues fits our model in glioblastomas that MOB3 modulates the cleavage of 
MST1. 
MST kinases have been shown to play a key role in hepatocyte hemostasis in mouse. Ablation of 
MST kinases in mouse liver results in hyperproliferation of hepatocytes and the progression of 
healthy liver to Hepatocellular Carcinoma (HCC) within 14 weeks. Interestingly, the majority of 
MST1 is cleaved in normal hepatocytes, proposing that cleaved MST1 might be a critical 
regulator of the quiescence of hepatocytes (114). Indeed, about 70% HCC samples show intact 
full-length MST1, suggesting that cleavage of MST1 is blocked in majority of HCC (114). These 
results indicate that de-regulation of MST1 cleavage might be a causer for the progression of 
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HCC (114, 201). Our results suggest hMOB3 might be a critical regulator of MST1 by inhibiting 
the cleavage of MST1 by direct protein-protein interaction. Therefore, it would be interesting to 
investigate the role of hMOB3 in liver cancer progression focusing on the cleavage process of 
MST1. A straightforward analysis would be to test the hMOB3 protein levels in paired adjacent 
non-neoplastic liver and HCC samples. 
Recently, MST1 has been identified as a critical regulator of apoptotic beta cell death and 
function, which is strongly activated in beta cells under diabetogenic conditions and induces 
apoptosis by upregulation of BCL-2 homolog-3 (BH3)-only protein BIM (202). Moreover, active 
MST1 phosphorylates PDX1 at Threonine 11 and promotes the ubiquitination mediated 
degradation of PDX1, which results in impaired insulin secretion (202). This study suggests that 
manipulation of MST1 may serve as potential therapeutic approach for diabetes (202). Our 
hMOB3 study indicates hMOB3 interacts with MST1 and inhibits the apoptotic cleavage of 
MST1. Therefore, it would be interesting to characterize the role(s) of hMOB3 in the beta cells 
under diabetogenic stress.  
Taken together, study of hMOB3 in the present thesis clearly suggests its biochemical role in 
regulating MST1 signaling and the pro-oncogenic roles of total hMOB3 proteins in 
glioblastomas. Manipulating hMOB3 sensitizes the glioma cells to chemotherapy drug induced 
apoptosis and blocks the tumorigenesis in vivo, pointing towards that hMOB3 might be a 
potential therapeutic target in GBM. Moreover, it is worth to extent the characterization the 
pathological roles of total hMOB3 proteins in colon cancer, liver cancer, mantle cell lymphomas, 
neurodegenerative diseases and metabolic disorders.       
 
78 
 
5. Reference 
This section contains the references cited in the Introduction and the General Discussion parts.  
1. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: 
kinase (catalytic) domain structure and classification. The FASEB Journal. 1995;9:576-96. 
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The Protein Kinase 
Complement of the Human Genome. Science. 2002;298:1912-34. 
3. Noble MEM, Endicott JA, Johnson LN. Protein Kinase Inhibitors: Insights into Drug 
Design from Structure. Science. 2004;303:1800-5. 
4. Tumaneng K, Russell Ryan C, Guan K-L. Organ Size Control by Hippo and TOR 
Pathways. Current biology : CB. 2012;22:R368-R79. 
5. Heitman J, Movva N, Hall M. Targets for cell cycle arrest by the immunosuppressant 
rapamycin in yeast. Science. 1991;253:905-9. 
6. Wullschleger S, Loewith R, Hall MN. TOR Signaling in Growth and Metabolism. Cell. 
2006;124:471-84. 
7. Hall MN. TOR Signalling: from Bench to Bedside: Stiftung Professor Dr. Max Cloëtta; 
2003. 
8. Inoki K, Li Y, Zhu T, Wu J, Guan K-L. TSC2 is phosphorylated and inhibited by Akt and 
suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-57. 
9. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the 
tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5:578-81. 
10. Howell JJ, Manning BD. mTOR couples cellular nutrient sensing to organismal 
metabolic homeostasis. Trends in Endocrinology & Metabolism. 2011;22:94-102. 
79 
 
11. Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic 
mosaics: the Drosophila lats gene encodes a putative protein kinase. Development. 
1995;121:1053-63. 
12. Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor 
gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the 
control of cell shape and proliferation. Genes & Development. 1995;9:534-46. 
13. Tapon N, Harvey KF, Bell DW, Wahrer DCR, Schiripo TA, Haber DA, et al. salvador 
Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer 
Cell Lines. Cell. 2002;110:467-78. 
14. Kango-Singh M, Nolo R, Tao C, Verstreken P, Hiesinger PR, Bellen HJ, et al. Shar-pei 
mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development. 
2002;129:5719-30. 
15. Wu S, Huang J, Dong J, Pan D. hippo Encodes a Ste-20 Family Protein Kinase that 
Restricts Cell Proliferation and Promotes Apoptosis in Conjunction with salvador and warts. Cell. 
2003;114:445-56. 
16. Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst Ortholog, hippo, Restricts 
Growth and Cell Proliferation and Promotes Apoptosis. Cell. 2003;114:457-67. 
17. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. Hippo promotes proliferation arrest 
and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5:914-20. 
18. Pantalacci S, Tapon N, Leopold P. The Salvador partner Hippo promotes apoptosis and 
cell-cycle exit in Drosophila. Nat Cell Biol. 2003;5:921-7. 
80 
 
19. Jia J, Zhang W, Wang B, Trinko R, Jiang J. The Drosophila Ste20 family kinase dMST 
functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes 
& Development. 2003;17:2514-9. 
20. Lai Z-C, Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N, et al. Control of Cell 
Proliferation and Apoptosis by Mob as Tumor Suppressor, Mats. Cell. 2005;120:675-85. 
21. Hergovich A, Stegert MR, Schmitz D, Hemmings BA. NDR kinases regulate essential 
cell processes from yeast to humans. Nat Rev Mol Cell Biol. 2006;7:253-64. 
22. Luca FC, Winey M. MOB1, an Essential Yeast Gene Required for Completion of Mitosis 
and Maintenance of Ploidy. Molecular Biology of the Cell. 1998;9:29-46. 
23. Komarnitsky SI, Chiang Y-C, Luca FC, Chen J, Toyn JH, Winey M, et al. DBF2 Protein 
Kinase Binds to and Acts through the Cell Cycle-Regulated MOB1 Protein. 1998. p. 2100-7. 
24. Wei X, Shimizu T, Lai Z-C. Mob as tumor suppressor is activated by Hippo kinase for 
growth inhibition in Drosophila. The EMBO Journal. 2007;26:1772-81. 
25. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo Signaling Pathway 
Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila 
Homolog of YAP. Cell. 2005;122:421-34. 
26. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a 
Universal Size-Control Mechanism in Drosophila and Mammals. Cell. 2007;130:1120-33. 
27. Wu S, Liu Y, Zheng Y, Dong J, Pan D. The TEAD/TEF Family Protein Scalloped 
Mediates Transcriptional Output of the Hippo Growth-Regulatory Pathway. Developmental Cell. 
2008;14:388-98. 
81 
 
28. Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J. The TEAD/TEF Family of 
Transcription Factor Scalloped Mediates Hippo Signaling in Organ Size Control. Developmental 
Cell. 2008;14:377-87. 
29. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene 
induction and growth control. Genes & Development. 2008;22:1962-71. 
30. Goulev Y, Fauny JD, Gonzalez-Marti B, Flagiello D, Silber J, Zider A. SCALLOPED 
Interacts with YORKIE, the Nuclear Effector of the Hippo Tumor-Suppressor Pathway in 
Drosophila. Current Biology. 2008;18:435-41. 
31. Pan D. The Hippo Signaling Pathway in Development and Cancer. Developmental Cell. 
2010;19:491-505. 
32. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein 
by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & 
Development. 2007;21:2747-61. 
33. Zhao B, Li L, Tumaneng K, Wang C-Y, Guan K-L. A coordinated phosphorylation by 
Lats and CK1 regulates YAP stability through SCFβ-TRCP. Genes & Development. 2010;24:72-
85. 
34. Koontz Laura M, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, Huang B, et al. The Hippo 
Effector Yorkie Controls Normal Tissue Growth by Antagonizing Scalloped-Mediated Default 
Repression. Developmental Cell. 2013;25:388-401. 
35. Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, et al. VGLL4 functions as a new tumor 
suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell 
Res. 2014;24:331-43. 
82 
 
36. Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, et al. A Peptide Mimicking VGLL4 
Function Acts as a YAP Antagonist Therapy against Gastric Cancer. Cancer Cell. 2014;25:166-
80. 
37. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, et al. The tumour-
suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell 
proliferation and apoptosis. Nat Cell Biol. 2006;8:27-36. 
38. Yu J, Zheng Y, Dong J, Klusza S, Deng W-M, Pan D. Kibra Functions as a Tumor 
Suppressor Protein that Regulates Hippo Signaling in Conjunction with Merlin and Expanded. 
Developmental Cell. 2010;18:288-99. 
39. Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H. The WW Domain Protein 
Kibra Acts Upstream of Hippo in Drosophila. Developmental Cell. 2010;18:309-16. 
40. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra Is a Regulator of the 
Salvador/Warts/Hippo Signaling Network. Developmental Cell. 2010;18:300-8. 
41. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, et al. The Merlin/NF2 Tumor 
Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in 
Mammals. Developmental Cell. 2010;19:27-38. 
42. Badouel C, Gardano L, Amin N, Garg A, Rosenfeld R, Le Bihan T, et al. The FERM-
Domain Protein Expanded Regulates Hippo Pathway Activity via Direct Interactions with the 
Transcriptional Activator Yorkie. Developmental Cell. 2009;16:411-20. 
43. Pellock BJ, Buff E, White K, Hariharan IK. The Drosophila tumor suppressors Expanded 
and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling. 
Developmental Biology. 2007;304:102-15. 
83 
 
44. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial Organization of Hippo Signaling 
at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2. Cell. 2013;154:1342-
55. 
45. Yu F-X, Guan K-L. The Hippo pathway: regulators and regulations. Genes & 
Development. 2013;27:355-71. 
46. Ling C, Zheng Y, Yin F, Yu J, Huang J, Hong Y, et al. The apical transmembrane protein 
Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to Expanded. 
Proceedings of the National Academy of Sciences. 2010;107:10532-7. 
47. Chen C-L, Gajewski KM, Hamaratoglu F, Bossuyt W, Sansores-Garcia L, Tao C, et al. 
The apical-basal cell polarity determinant Crumbs regulates Hippo signaling in Drosophila. 
Proceedings of the National Academy of Sciences. 2010;107:15810-5. 
48. Robinson BS, Huang J, Hong Y, Moberg KH. Crumbs Regulates Salvador/Warts/Hippo 
Signaling in Drosophila via the FERM-Domain Protein Expanded. Current Biology. 
2010;20:582-90. 
49. Grzeschik NA, Parsons LM, Allott ML, Harvey KF, Richardson HE. Lgl, aPKC, and 
Crumbs Regulate the Salvador/Warts/Hippo Pathway through Two Distinct Mechanisms. 
Current Biology. 2010;20:573-81. 
50. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, et al. 
The Crumbs Complex Couples Cell Density Sensing to Hippo-Dependent Control of the TGF-β-
SMAD Pathway. Developmental Cell. 2010;19:831-44. 
51. Parsons LM, Grzeschik NA, Allott M, Richardson H. Lgl/aPKC and Crb regulate the 
Salvador/Warts/Hippo pathway. Fly. 2010;4:288-93. 
84 
 
52. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, et al. A genetic screen 
identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway. Nat Cell Biol. 
2014;16:108-17. 
53. Nguyen HB, Babcock JT, Wells CD, Quilliam LA. LKB1 tumor suppressor regulates 
AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. 
Oncogene. 2013;32:4100-9. 
54. Huang H-L, Wang S, Yin M-X, Dong L, Wang C, Wu W, et al. Par-1 Regulates Tissue 
Growth by Influencing Hippo Phosphorylation Status and Hippo-Salvador Association. PLoS 
Biol. 2013;11:e1001620. 
55. Skouloudaki K, Puetz M, Simons M, Courbard J-R, Boehlke C, Hartleben B, et al. 
Scribble participates in Hippo signaling and is required for normal zebrafish pronephros 
development. Proceedings of the National Academy of Sciences. 2009;106:8579-84. 
56. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The 
Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell. 
2011;147:759-72. 
57. Bennett FC, Harvey KF. Fat Cadherin Modulates Organ Size in Drosophila via the 
Salvador/Warts/Hippo Signaling Pathway. Current Biology. 2006;16:2101-10. 
58. Silva E, Tsatskis Y, Gardano L, Tapon N, McNeill H. The Tumor-Suppressor Gene fat 
Controls Tissue Growth Upstream of Expanded in the Hippo Signaling Pathway. Current 
Biology. 2006;16:2081-9. 
59. Willecke M, Hamaratoglu F, Kango-Singh M, Udan R, Chen C-l, Tao C, et al. The Fat 
Cadherin Acts through the Hippo Tumor-Suppressor Pathway to Regulate Tissue Size. Current 
Biology. 2006;16:2090-100. 
85 
 
60. Grusche FA, Richardson HE, Harvey KF. Upstream Regulation of the Hippo Size 
Control Pathway. Current Biology. 2010;20:R574-R82. 
61. Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 
2011;138:9-22. 
62. Genevet A, Tapon N. The Hippo pathway and apico–basal cell polarity. Biochemical 
Journal. 2011;436:213-24. 
63. Yu F-X, Zhao B, Panupinthu N, Jewell Jenna L, Lian I, Wang Lloyd H, et al. Regulation 
of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling. Cell. 2012;150:780-91. 
64. Mo J-S, Yu F-X, Gong R, Brown JH, Guan K-L. Regulation of the Hippo–YAP pathway 
by protease-activated receptors (PARs). Genes & Development. 2012;26:2138-43. 
65. Miller E, Yang J, DeRan M, Wu C, Su Andrew I, Bonamy Ghislain MC, et al. 
Identification of Serum-Derived Sphingosine-1-Phosphate as a Small Molecule Regulator of 
YAP. Chemistry & Biology. 2012;19:955-62. 
66. Wada K-I, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell 
morphology and stress fibers. Development. 2011;138:3907-14. 
67. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of 
YAP/TAZ in mechanotransduction. Nature. 2011;474:179-83. 
68. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, et al. A 
Mechanical Checkpoint Controls Multicellular Growth through YAP/TAZ Regulation by Actin-
Processing Factors. Cell. 2013;154:1047-59. 
69. Zhao B, Li L, Wang L, Wang C-Y, Yu J, Guan K-L. Cell detachment activates the Hippo 
pathway via cytoskeleton reorganization to induce anoikis. Genes & Development. 2012;26:54-
68. 
86 
 
70. Sansores-Garcia L, Bossuyt W, Wada K-I, Yonemura S, Tao C, Sasaki H, et al. 
Modulating F-actin organization induces organ growth by affecting the Hippo pathway. The 
EMBO Journal. 2011;30:2325-35. 
71. Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by 
YAP and TAZ. Nat Rev Mol Cell Biol. 2012;13:591-600. 
72. Creasy CL, Chernoff J. Cloning and Characterization of a Human Protein Kinase with 
Homology to Ste20. Journal of Biological Chemistry. 1995;270:21695-700. 
73. Creasy CL, Chernoff J. Cloning and characterization of a member of the MST subfamily 
of Ste20-like kinases. Gene. 1995;167:303-6. 
74. Taylor LK, Wang HC, Erikson RL. Newly identified stress-responsive protein kinases, 
Krs-1 and Krs-2. Proceedings of the National Academy of Sciences. 1996;93:10099-104. 
75. Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F, Barrufet LR. Protein kinases of the 
Hippo pathway: Regulation and substrates. Seminars in Cell & Developmental Biology. 
2012;23:770-84. 
76. Oh HJ, Lee K-K, Song SJ, Jin MS, Song MS, Lee JH, et al. Role of the Tumor 
Suppressor RASSF1A in Mst1-Mediated Apoptosis. Cancer Research. 2006;66:2562-9. 
77. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, et al. RASSF1A 
Elicits Apoptosis through an MST2 Pathway Directing Proapoptotic Transcription by the p73 
Tumor Suppressor Protein. Molecular Cell. 2007;27:962-75. 
78. Creasy CL, Ambrose DM, Chernoff J. The Ste20-like Protein Kinase, Mst1, Dimerizes 
and Contains an Inhibitory Domain. Journal of Biological Chemistry. 1996;271:21049-53. 
87 
 
79. Glantschnig H, Rodan GA, Reszka AA. Mapping of MST1 Kinase Sites of 
Phosphorylation: ACTIVATION AND AUTOPHOSPHORYLATION. Journal of Biological 
Chemistry. 2002;277:42987-96. 
80. Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, 
Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and 
phosphorylation. FEBS Journal. 2006;273:4264-76. 
81. Graves JD, Gotoh Y, Draves KE, Ambrose D, Han DKM, Wright M, et al. Caspase-
mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. 
EMBO J. 1998;17:2224-34. 
82. Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S. MST, a physiological caspase 
substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. The 
Journal of biological chemistry. 2001;276:19276-85. 
83. Ura S, Masuyama N, Graves JD, Gotoh Y. Caspase cleavage of MST1 promotes nuclear 
translocation and chromatin condensation. Proceedings of the National Academy of Sciences. 
2001;98:10148-53. 
84. Kyung-Kwon Lee MM, Eisuke Nishida, Satoshi Tsubuki, Swi-ichi Kawashima, Kazuhiro 
Sakamaki and Shin Yonehara. Proteolytic activation of MST/Krs, STE20-related protein kinase, 
by caspase during apoptosis. Oncogene. 1998;16:3029-37. 
85. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al. Apoptotic 
Phosphorylation of Histone H2B Is Mediated by Mammalian Sterile Twenty Kinase. Cell. 
2003;113:507-17. 
88 
 
86. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villén J, Becker EBE, et al. A Conserved 
MST-FOXO Signaling Pathway Mediates Oxidative-Stress Responses and Extends Life Span. 
Cell. 2006;125:987-1001. 
87. Ura S, Nishina H, Gotoh Y, Katada T. Activation of the c-Jun N-Terminal Kinase 
Pathway by MST1 Is Essential and Sufficient for the Induction of Chromatin Condensation 
during Apoptosis. Molecular and Cellular Biology. 2007;27:5514-22. 
88. Ura S, Masuyama N, Graves JD, Gotoh Y. MST1-JNK promotes apoptosis via caspase-
dependent and independent pathways. Genes to Cells. 2001;6:519-30. 
89. Bi W, Xiao L, Jia Y, Wu J, Xie Q, Ren J, et al. c-Jun N-terminal Kinase Enhances 
MST1-mediated Pro-apoptotic Signaling through Phosphorylation at Serine 82. Journal of 
Biological Chemistry. 2010;285:6259-64. 
90. Densham RM, O'Neill E, Munro J, König I, Anderson K, Kolch W, et al. MST Kinases 
Monitor Actin Cytoskeletal Integrity and Signal via c-Jun N-Terminal Kinase Stress-Activated 
Kinase To Regulate p21Waf1/Cip1 Stability. Molecular and Cellular Biology. 2009;29:6380-90. 
91. Lin Y, Khokhlatchev A, Figeys D, Avruch J. Death-associated Protein 4 Binds MST1 
and Augments MST1-induced Apoptosis. Journal of Biological Chemistry. 2002;277:47991-
8001. 
92. Yuan F, Xie Q, Wu J, Bai Y, Mao B, Dong Y, et al. MST1 Promotes Apoptosis through 
Regulating Sirt1-dependent p53 Deacetylation. Journal of Biological Chemistry. 2011;286:6940-
5. 
93. Boggiano Julian C, Vanderzalm Pamela J, Fehon Richard G. Tao-1 Phosphorylates 
Hippo/MST Kinases to Regulate the Hippo-Salvador-Warts Tumor Suppressor Pathway. 
Developmental Cell. 2011;21:888-95. 
89 
 
94. Poon Carole LC, Lin Jane I, Zhang X, Harvey Kieran F. The Sterile 20-like Kinase Tao-1 
Controls Tissue Growth by Regulating the Salvador-Warts-Hippo Pathway. Developmental Cell. 
2011;21:896-906. 
95. Poon Carole LC, Zhang X, Lin Jane I, Manning Samuel A, Harvey Kieran F. 
Homeodomain-Interacting Protein Kinase Regulates Hippo Pathway-Dependent Tissue Growth. 
Current Biology. 2012;22:1587-94. 
96. Chen J, Verheyen Esther M. Homeodomain-Interacting Protein Kinase Regulates Yorkie 
Activity to Promote Tissue Growth. Current Biology. 2012;22:1582-6. 
97. Xiao L, Chen D, Hu P, Wu J, Liu W, Zhao Y, et al. The c-Abl-MST1 Signaling Pathway 
Mediates Oxidative Stress-Induced Neuronal Cell Death. The Journal of Neuroscience. 
2011;31:9611-9. 
98. Liu W, Wu J, Xiao L, Bai Y, Qu A, Zheng Z, et al. Regulation of Neuronal Cell Death by 
c-Abl-Hippo/MST2 Signaling Pathway. PLoS ONE. 2012;7:e36562. 
99. Mou F, Praskova M, Xia F, Van Buren D, Hock H, Avruch J, et al. The Mst1 and Mst2 
kinases control activation of rho family GTPases and thymic egress of mature thymocytes. The 
Journal of Experimental Medicine. 2012;209:741-59. 
100. Jang S-W, Yang S-J, Srinivasan S, Ye K. Akt Phosphorylates MstI and Prevents Its 
Proteolytic Activation, Blocking FOXO3 Phosphorylation and Nuclear Translocation. Journal of 
Biological Chemistry. 2007;282:30836-44. 
101. Yuan Z, Kim D, Shu S, Wu J, Guo J, Xiao L, et al. Phosphoinositide 3-Kinase/Akt 
Inhibits MST1-Mediated Pro-apoptotic Signaling through Phosphorylation of Threonine 120. 
Journal of Biological Chemistry. 2010;285:3815-24. 
90 
 
102. Kisaayak Collak F, Yagiz K, Luthringer DJ, Erkaya B, Cinar B. Threonine-120 
Phosphorylation Regulated by Phosphoinositide-3-Kinase/Akt and Mammalian Target of 
Rapamycin Pathway Signaling Limits the Antitumor Activity of Mammalian Sterile 20-Like 
Kinase 1. Journal of Biological Chemistry. 2012. 
103. Collak FK, Yagiz K, Luthringer DJ, Erkaya B, Cinar B. Threonine-120 phosphorylation 
regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway 
signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. The Journal of 
biological chemistry. 2012;287:23698-709. 
104. Cinar B, Fang P-K, Lutchman M, Di Vizio D, Adam RM, Pavlova N, et al. The pro-
apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J. 
2007;26:4523-34. 
105. Kim D, Shu S, Coppola MD, Kaneko S, Yuan Z-q, Cheng JQ. Regulation of Proapoptotic 
Mammalian ste20–Like Kinase MST2 by the IGF1-Akt Pathway. PLoS ONE. 2010;5:e9616. 
106. Wehr MC, Holder MV, Gailite I, Saunders RE, Maile TM, Ciirdaeva E, et al. Salt-
inducible kinases regulate growth through the Hippo signalling pathway in Drosophila. Nat Cell 
Biol. 2013;15:61-71. 
107. O'Neill E, Rushworth L, Baccarini M, Kolch W. Role of the Kinase MST2 in 
Suppression of Apoptosis by the Proto-Oncogene Product Raf-1. Science. 2004;306:2267-70. 
108. O’Neill E, Kolch W. Taming the Hippo: Raf-1 Controls Apoptosis by Suppressing 
MST2/Hippo. Cell Cycle. 2005;4:365-7. 
109. Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T, Kolch W. Proapoptotic 
Kinase MST2 Coordinates Signaling Crosstalk between RASSF1A, Raf-1, and Akt. Cancer 
Research. 2010;70:1195-203. 
91 
 
110. Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, et al. Mst1 Is an Interacting Protein that 
Mediates PHLPPs' Induced Apoptosis. Molecular Cell. 2010;38:512-23. 
111. Guo C, Zhang X, Pfeifer GP. The Tumor Suppressor RASSF1A Prevents 
Dephosphorylation of the Mammalian STE20-like Kinases MST1 and MST2. Journal of 
Biological Chemistry. 2011;286:6253-61. 
112. Kilili GK, Kyriakis JM. Mammalian Ste20-like Kinase (Mst2) Indirectly Supports Raf-
1/ERK Pathway Activity via Maintenance of Protein Phosphatase-2A Catalytic Subunit Levels 
and Consequent Suppression of Inhibitory Raf-1 Phosphorylation. Journal of Biological 
Chemistry. 2010;285:15076-87. 
113. Oh S, Lee D, Kim T, Kim T-S, Oh HJ, Hwang CY, et al. Crucial Role for Mst1 and Mst2 
Kinases in Early Embryonic Development of the Mouse. Molecular and Cellular Biology. 
2009;29:6309-20. 
114. Zhou D, Conrad C, Xia F, Park J-S, Payer B, Yin Y, et al. Mst1 and Mst2 Maintain 
Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through 
Inactivation of the Yap1 Oncogene. Cancer Cell. 2009;16:425-38. 
115. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 
kinases play essential roles in organ size control and tumor suppression. Proceedings of the 
National Academy of Sciences. 2010;107:1431-6. 
116. Qin F, Tian J, Zhou D, Chen L. Mst1 and Mst2 kinases: regulations and diseases. Cell & 
Bioscience. 2013;3:31. 
117. Lee K-P, Lee J-H, Kim T-S, Kim T-H, Park H-D, Byun J-S, et al. The Hippo–Salvador 
pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proceedings 
of the National Academy of Sciences. 2010;107:8248-53. 
92 
 
118. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo 
growth and tumor suppressor pathway in the mammalian liver. Proceedings of the National 
Academy of Sciences. 2010;107:1437-42. 
119. Lam-Himlin D, Daniels J, Gayyed M, Dong J, Maitra A, Pan D, et al. The Hippo 
Pathway in Human Upper Gastrointestinal Dysplasia and Carcinoma: A Novel Oncogenic 
Pathway. J Gastrointest Canc. 2006;37:103-9. 
120. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 
Increases Organ Size and Expands Undifferentiated Progenitor Cells. Current Biology. 
2007;17:2054-60. 
121. Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, et al. Mst1 and Mst2 protein 
kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-
associated protein (Yap) overabundance. Proceedings of the National Academy of Sciences. 
2011. 
122. Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D. The Hippo signaling pathway 
restricts the oncogenic potential of an intestinal regeneration program. Genes & Development. 
2010;24:2383-8. 
123. George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. Hippo Signaling 
Regulates Pancreas Development through Inactivation of Yap. Molecular and Cellular Biology. 
2012;32:5116-28. 
124. Gao T, Zhou D, Yang C, Singh T, Penzo–Méndez A, Maddipati R, et al. Hippo Signaling 
Regulates Differentiation and Maintenance in the Exocrine Pancreas. Gastroenterology. 
2013;144:1543-53.e1. 
93 
 
125. Matsui Y, Nakano N, Shao D, Gao S, Luo W, Hong C, et al. Lats2 Is a Negative 
Regulator of Myocyte Size in the Heart. Circulation Research. 2008;103:1309-18. 
126. Heallen T, Morikawa Y, Leach J, Zhang M, Xiao Y, Martin J. Hippo Signaling in Heart 
Development. In: Oren M, Aylon Y, editors. The Hippo Signaling Pathway and Cancer: Springer 
New York; 2013. p. 293-304. 
127. Zhou D, Medoff BD, Chen L, Li L, Zhang X-f, Praskova M, et al. The Nore1B/Mst1 
complex restrains antigen receptor-induced proliferation of naïve T cells. Proceedings of the 
National Academy of Sciences. 2008;105:20321-6. 
128. Katagiri K, Imamura M, Kinashi T. Spatiotemporal regulation of the kinase Mst1 by 
binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol. 
2006;7:919 - 28. 
129. Dong Y, Du X, Ye J, Han M, Xu T, Zhuang Y, et al. A cell-intrinsic role for Mst1 in 
regulating thymocyte egress. J Immunol. 2009;183:3865 - 72. 
130. Katagiri K, Katakai T, Ebisuno Y, Ueda Y, Okada T, Kinashi T. Mst1 controls 
lymphocyte trafficking and interstitial motility within lymph nodes. EMBO J. 2009;28:1319 - 31. 
131. Choi J, Oh S, Lee D, Oh H, Park J, Lee S, et al. Mst1-FoxO signaling protects Naive T 
lymphocytes from cellular oxidative stress in mice. PloS one. 2009;4:e8011. 
132. Nehme N, Pachlopnik Schmid J, Debeurme F, Andre-Schmutz I, Lim A, Nitschke P, et al. 
MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective 
naive T cells survival. Blood. 2012;119:3458 - 68. 
133. Crequer A, Picard C, Patin E, D'Amico A, Abhyankar A, Munzer M, et al. Inherited 
MST1 deficiency underlies susceptibility to EV-HPV infections. PloS one. 2012;7:e44010. 
94 
 
134. Dong Y, Du X, Ye J, Han M, Xu T, Zhuang Y, et al. A Cell-Intrinsic Role for Mst1 in 
Regulating Thymocyte Egress. The Journal of Immunology. 2009;183:3865-72. 
135. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. 
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. 
Nature. 2004;427:355-60. 
136. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat 
Immunol. 2007;8:1295-301. 
137. Cyster JG, Schwab SR. Sphingosine-1-Phosphate and Lymphocyte Egress from 
Lymphoid Organs. Annual Review of Immunology. 2012;30:69-94. 
138. Ueda Y, Katagiri K, Tomiyama T, Yasuda K, Habiro K, Katakai T, et al. Mst1 regulates 
integrin-dependent thymocyte trafficking and antigen recognition in the thymus. Nat Commun. 
2012;3:1098. 
139. Nishio M, Hamada K, Kawahara K, Sasaki M, Noguchi F, Chiba S, et al. Cancer 
susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. The Journal of Clinical 
Investigation. 2012;122:4505-18. 
140. Kohler RS, Schmitz D, Cornils H, Hemmings BA, Hergovich A. Differential NDR/LATS 
Interactions with the Human MOB Family Reveal a Negative Role for Human MOB2 in the 
Regulation of Human NDR Kinases. Molecular and Cellular Biology. 2010;30:4507-20. 
141. Goudreault M, D’Ambrosio LM, Kean MJ, Mullin MJ, Larsen BG, Sanchez A, et al. A 
PP2A Phosphatase High Density Interaction Network Identifies a Novel Striatin-interacting 
Phosphatase and Kinase Complex Linked to the Cerebral Cavernous Malformation 3 (CCM3) 
Protein. Molecular & Cellular Proteomics. 2009;8:157-71. 
95 
 
142. Bichsel SJ, Tamaskovic R, Stegert MR, Hemmings BA. Mechanism of Activation of 
NDR (Nuclear Dbf2-related) Protein Kinase by the hMOB1 Protein. Journal of Biological 
Chemistry. 2004;279:35228-35. 
143. Hergovich A, Bichsel SJ, Hemmings BA. Human NDR Kinases Are Rapidly Activated 
by MOB Proteins through Recruitment to the Plasma Membrane and Phosphorylation. Molecular 
and Cellular Biology. 2005;25:8259-72. 
144. Hergovich A, Schmitz D, Hemmings BA. The human tumour suppressor LATS1 is 
activated by human MOB1 at the membrane. Biochemical and Biophysical Research 
Communications. 2006;345:50-8. 
145. Hergovich A. MOB control: Reviewing a conserved family of kinase regulators. Cellular 
Signalling. 2011;23:1433-40. 
146. Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D, Hemmings BA. NDR 
Kinase Is Activated by RASSF1A/MST1 in Response to Fas Receptor Stimulation and Promotes 
Apoptosis. Current Biology. 2008;18:1889-95. 
147. Hergovich A, Kohler RS, Schmitz D, Vichalkovski A, Cornils H, Hemmings BA. The 
MST1 and hMOB1 Tumor Suppressors Control Human Centrosome Duplication by Regulating 
NDR Kinase Phosphorylation. Current Biology. 2009;19:1692-702. 
148. Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B Phosphorylation by MST1 and 
MST2 Inhibits Cell Proliferation. Current Biology. 2008;18:311-21. 
149. Lignitto L, Arcella A, Sepe M, Rinaldi L, Delle Donne R, Gallo A, et al. Proteolysis of 
MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma 
growth. Nat Commun. 2013;4:1822. 
96 
 
150. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev 
Mol Cell Biol. 2010;11:9-22. 
151. Hergovich A, Cornils H, Hemmings BA. Mammalian NDR protein kinases: From 
regulation to a role in centrosome duplication. Biochimica et Biophysica Acta (BBA) - Proteins 
and Proteomics. 2008;1784:3-15. 
152. Hergovich A. Regulation and functions of mammalian LATS/NDR kinases: looking 
beyond canonical Hippo signalling. Cell & Bioscience. 2013;3:32. 
153. Stegert MR, Hergovich A, Tamaskovic R, Bichsel SJ, Hemmings BA. Regulation of 
NDR Protein Kinase by Hydrophobic Motif Phosphorylation Mediated by the Mammalian 
Ste20-Like Kinase MST3. Molecular and Cellular Biology. 2005;25:11019-29. 
154. Cornils H, Kohler RS, Hergovich A, Hemmings BA. Human NDR Kinases Control G1/S 
Cell Cycle Transition by Directly Regulating p21 Stability. Molecular and Cellular Biology. 
2011;31:1382-95. 
155. Hirabayashi S, Nakagawa K, Sumita K, Hidaka S, Kawai T, Ikeda M, et al. Threonine 74 
of MOB1 is a putative key phosphorylation site by MST2 to form the scaffold to activate nuclear 
Dbf2-related kinase 1. Oncogene. 2008;27:4281-92. 
156. Chiba S, Ikeda M, Katsunuma K, Ohashi K, Mizuno K. MST2- and Furry-Mediated 
Activation of NDR1 Kinase Is Critical for Precise Alignment of Mitotic Chromosomes. Current 
biology : CB. 2009;19:675-81. 
157. Millward TA, Hess D, Hemmings BA. Ndr Protein Kinase Is Regulated by 
Phosphorylation on Two Conserved Sequence Motifs. Journal of Biological Chemistry. 
1999;274:33847-50. 
97 
 
158. Emoto K, Parrish JZ, Jan LY, Jan Y-N. The tumour suppressor Hippo acts with the NDR 
kinases in dendritic tiling and maintenance. Nature. 2006;443:210-3. 
159. Emoto K, He Y, Ye B, Grueber WB, Adler PN, Jan LY, et al. Control of Dendritic 
Branching and Tiling by the Tricornered-Kinase/Furry Signaling Pathway in Drosophila Sensory 
Neurons. Cell. 2004;119:245-56. 
160. St John MAR, Tao W, Fei X, Fukumoto R, Carcangiu ML, Brownstein DG, et al. Mice 
deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat 
Genet. 1999;21:182-6. 
161. Hergovich A, Lamla S, Nigg EA, Hemmings BA. Centrosome-Associated NDR Kinase 
Regulates Centrosome Duplication. Molecular Cell. 2007;25:625-34. 
162. Cornils H, Kohler RS, Hergovich A, Hemmings BA. Downstream of human NDR 
kinases: Impacting on c-myc and p21 protein stability to control cell cycle progression. Cell 
Cycle. 2011;10:1897-904. 
163. Cornils H, Stegert MR, Hergovich A, Hynx D, Schmitz D, Dirnhofer S, et al. Ablation of 
the Kinase NDR1 Predisposes Mice to the Development of T Cell Lymphoma. Sci Signal. 
2010;3:ra47-. 
164. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of 
malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10:319-31. 
165. Van Meir EG, Hadjipanayis CG, Norden AD, Shu H-K, Wen PY, Olson JJ. Exciting New 
Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. CA: A Cancer 
Journal for Clinicians. 2010;60:166-93. 
98 
 
166. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant 
astrocytic glioma: genetics, biology, and paths to treatment. Genes & Development. 
2007;21:2683-710. 
167. DeAngelis LM. Brain Tumors. New England Journal of Medicine. 2001;344:114-23. 
168. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. 
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England 
Journal of Medicine. 2005;352:987-96. 
169. Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in 
glioblastoma. Expert Review of Neurotherapeutics. 2009;9:519-34. 
170. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells 
promote radioresistance by preferential activation of the DNA damage response. Nature. 
2006;444:756-60. 
171. Zhai G, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M, et al. Radiation 
Enhances the Invasive Potential of Primary Glioblastoma Cells via Activation of the Rho 
Signaling Pathway. J Neurooncol. 2006;76:227-37. 
172. Sanai N, Alvarez-Buylla A, Berger MS. Neural Stem Cells and the Origin of Gliomas. 
New England Journal of Medicine. 2005;353:811-22. 
173. Joo KM, Kim SY, Jin X, Song SY, Kong D-S, Lee J, II, et al. Clinical and biological 
implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 
2008;88:808-15. 
174. Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, et al. 
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. 
International Journal of Cancer. 2008;122:761-8. 
99 
 
175. Son MJ, Woolard K, Nam D-H, Lee J, Fine HA. SSEA-1 Is an Enrichment Marker for 
Tumor-Initiating Cells in Human Glioblastoma. Cell Stem Cell. 2009;4:440-52. 
176. Strojnik T, Røsland GV, Sakariassen PO, Kavalar R, Lah T. Neural stem cell markers, 
nestin and musashi proteins, in the progression of human glioma: correlation of nestin with 
prognosis of patient survival. Surgical Neurology. 2007;68:133-43. 
177. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent 
glioblastoma—are we there yet? Neuro-Oncology. 2013;15:4-27. 
178. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT 
Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of 
Medicine. 2005;352:997-1003. 
179. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased 
expression of the epidermal growth factor receptor gene in malignant gliomas is invariably 
associated with gene amplification. Proceedings of the National Academy of Sciences. 
1987;84:6899-903. 
180. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic 
Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. 
Clinical Cancer Research. 2005;11:1462-6. 
181. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. 
Structural alterations of the epidermal growth factor receptor gene in human gliomas. 
Proceedings of the National Academy of Sciences. 1992;89:2965-9. 
182. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. 
Journal of Clinical Neuroscience. 2009;16:748-54. 
100 
 
183. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived Growth 
Factor (PDGF) Autocrine Signaling Regulates Survival and Mitogenic Pathways in Glioblastoma 
Cells: Evidence That the Novel PDGF-C and PDGF-D Ligands May Play a Role in the 
Development of Brain Tumors. Cancer Research. 2002;62:3729-35. 
184. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis 
in brain tumours. Nat Rev Neurosci. 2007;8:610-22. 
185. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev 
Cancer. 2013;advance online publication. 
186. Lau Y-KI, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q. Merlin Is a Potent 
Inhibitor of Glioma Growth. Cancer Research. 2008;68:5733-42. 
187. Xu Y, Stamenkovic I, Yu Q. CD44 Attenuates Activation of the Hippo Signaling 
Pathway and Is a Prime Therapeutic Target for Glioblastoma. Cancer Research. 2010;70:2455-
64. 
188. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al. The NF2 tumor 
suppressor gene product, merlin, mediates contact inhibition of growth through interactions with 
CD44. Genes & Development. 2001;15:968-80. 
189. Bhat KPL, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et 
al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant 
glioma. Genes & Development. 2011;25:2594-609. 
190. Skinner M. Cancer stem cells: TAZ takes centre stage. Nat Rev Cancer. 2012;12:82-3. 
191. Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-Associated Protein 1 Is 
Widely Expressed in Human Brain Tumors and Promotes Glioblastoma Growth. Journal of 
Neuropathology & Experimental Neurology. 2011;70:568-77 10.1097/NEN.0b013e31821ff8d8. 
101 
 
192. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic 
silencing to functional characterization. Biochimica et Biophysica Acta (BBA) - Reviews on 
Cancer. 2009;1796:114-28. 
193. Seidel C, Schagdarsurengin U, Blümke K, Würl P, Pfeifer GP, Hauptmann S, et al. 
Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Molecular 
Carcinogenesis. 2007;46:865-71. 
194. Hisaoka M, Tanaka A, Hashimoto H. Molecular Alterations of h-warts//LATS1 Tumor 
Suppressor in Human Soft Tissue Sarcoma. Lab Invest. 0000;82:1427-35. 
195. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee S-J, Anders RA, et al. Genetic and 
pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of 
YAP. Genes & Development. 2012;26:1300-5. 
196. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, et al. DNA 
Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy 
of Clinically Localized Prostate Cancer. Journal of Clinical Oncology. 2013;31:3250-8. 
197. Beà S, Salaverria I, Armengol L, Pinyol M, Fernández V, Hartmann EM, et al. 
Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell 
lymphoma revealed by integrative high-resolution whole-genome profiling. Blood. 
2009;113:3059-69. 
198. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, et al. Pathway 
discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and 
copy number profiling. Blood. 2010;116:953-61. 
102 
 
199. Boxer AL, Mackenzie IR, Boeve BF, Baker M, Seeley WW, Crook R, et al. Clinical, 
neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. 
Journal of Neurology, Neurosurgery & Psychiatry. 2011;82:196-203. 
200. Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, et 
al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the 
frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification 
study. The Lancet Neurology. 2012;11:54-65. 
201. Avruch J, Zhou D, Fitamant J, Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver 
size and tumour development. Br J Cancer. 2011;104:24-32. 
202. Ardestani A, Paroni F, Azizi Z, Kaur S, Khobragade V, Yuan T, et al. MST1 is a key 
regulator of beta cell apoptosis and dysfunction in diabetes. Nat Med. 2014;advance online 
publication. 
 
 
 
 
 
 
 
 
 
103 
 
6. Acknowledgement 
I would like to sincerely thank Dr. Brian A. Hemmings FRS for giving me the opportunity to do 
my PhD in his laboratory and for his support during the past four years. I am very grateful to 
Prof. Dr. Michael N. Hall and Prof. Dr. Patrick Matthias for their continuous support as members 
of my thesis committee and to Prof. Dr. Stephan Frank for his help with GBM samples and 
helpful comments on the manuscript. I would like to thank Dr. Alexander Hergovich for his 
insightful discussion and comments on my project and manuscript. I am grateful to Dr. Jason 
Gill for his collaboration in my in vivo project. 
I would like to thank Dr. Debora Schmitz for her advices on general scientific writing and 
constructive comments on my manuscript. I am grateful to Dr. Reto Kohler and Dr. Hauke 
Cornils for their helpful discussion during the initial phase of on my projects. A special thank 
goes to Dr. Gongda Xue and Dr. Yuhua Wang for their consistent help with scientific discussion 
and experimental designing. I am thankful to Dr. Christian Hundsrucker for his bioinformatics 
support. I would like to also thank Peter Cron and Debby Hynes with their continuous help with 
molecular biology and in vivo study.        
I am also grateful to Dr. Simon Schultze for the collaboration with liver carcinogenesis and liver 
targeting and his generous sharing scientific documents with me. I am thankful to Dr. Gerald 
Moncayo and all members of Hemmings lab for their help and atmosphere.  
I am extremely grateful to my wife Zifei for her understanding and consistent support and for the 
big surprise of Yihan. I am also very thankful to my parents and families in China. This thesis 
would not be possible without their continuous support and love.  
104 
 
7. Curriculum vitae 
Fengyuan Tang 
Friedrich Miescher Institute for Biomedical Research 
Maulbeerstrasse 66, WRO-1066.346 
CH-4058, Basel 
 
Personal details 
Marital status:  Married 
Date of birth:  12.10.1985 in Liyang, China 
Nationality:  Chinese 
Telephone:  +41-78-966-1216 
E-mail:  fengyuan.tang@fmi.ch 
 
 
Education  
Jul. 2010 
- Today 
Friedrich Miescher Institute, University of Basel (Basel, Switzerland) 
Ph.D student in Biochemistry 
 
Sep. 2007 
-Jun. 2010 
Nanjing University (Nanjing, China) 
M.Sc in Biochemistry and Molecular Biology 
 
Sep. 2003 
-Jun. 2007 
Nanjing University  (Nanjing , China)  
B. Sc in Biotechnology 
 
 
List of publications 
 
Tang F, Zhang L, Xue G, Hynx D, Wang Y, Cron PD, Hundsrucker C, Hergovich A, Frank S, 
Hemmings BA, Schmitz-Rohmer D. hMOB3 modulates apoptotic MST1 signaling and supports 
tumor growth in glioblastoma multiforme. Cancer Research; 74(14);3779-89. 
Tang F, Gill J, Cornils H, Hynx D, Zhang L, Xue G, Schmitz-Rohmer D, Matthias P, Hemmings 
BA. NDR kinases control mature thymocytes egress downstream of MST1 signaling. Manuscript 
under preparation. 
105 
 
Zhang L, Tang F, Hynx D, Hemmings BA, Schimitz-Rohmer D. Mammalian NDR kinases 
function as tumor suppressors in the intestinal epithelium. Manuscript under preparation.  
Schmitz-Rohmer D, Probst S, Tang F, Hergovich A, Kohler R, Yang ZZ, Zeller R, Hemmings 
BA. Mammalian NDR kinases are essential for embryonic development and impact on Notch 
signaling in vivo. Manuscript under preparation. 
Xue G, Wang Y, Hynx D, Tang F, Orso F, Hirschmann P, Cron P, Roloff T, Muraro MG, 
Spagnoli G, Zippelius A, Taverna D, Ruegg C, Merghoub T, Dirnhofer S, Hemmings BA. 
mTORC1/autophagy-regulated MerTK confers resistance to Vemurafenib in BRAFV600E 
melanoma. Submitted. 
Lu W, Sun Z, Tang Y, Chen J, Tang F, Zhang J, Liu JN. Split intein facilitated tag affinity 
purification for recombinant proteins with controllable tag removal by inducible auto-cleavage. 
Journal of Chromatography A 2011, 1218 (18): 2553-2560 
Qian C, Liu JN, Tang F, Yuan D, Guo Z and Zhang J. A novel strategy for proteome-wide 
ligand screening using cross-linked phage matrices. Journal of Biological Chemistry 2010, 285: 
9367-9372 
 
Grants 
Swiss National Science Foundation SNF 31003A_138287.  01.12.2011-30.11.2014 
 
Attended Conferences 
NCCR Molecular Oncology Concluding Symposium; Lausanne, 2013 
TOR, PI3K and Akt - 20 years on; Basel, 2011  
FMI 40th Anniversary Symposium;  Basel, 2010 
Internal FMI annual meeting; 2009-2013 (Poster presentation) 
 
